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Abstract 
Positron emission tomography (PET) is a medical imaging technique widely used for cancer 
diagnostics. The objective of this study was to investigate whether dynamic 18F-FDG PET 
imaging could be used to characterize tumors and monitor treatment response.  
In this study we have looked at human prostate and breast cancer xenografts in nude 
mice. The first set was the androgen sensitive CWR22 prostate cancer, where the untreated 
tumors were compared with tumors that had received a dose of 7.5 Gy. The second set 
compared the basal-like MAS 98.12 with the luminal-like MAS 98.06 xenografts of breast 
cancer.  
By using different methods and techniques, a search for distinctions between groups 
have been conducted. It was first noticed that the very basic time activity curve (TAC) itself 
differed between the groups. For the latest time points, there was statistically significant 
differences between groups within each data set. Using a two-compartment pharmacokinetic 
model, rate constants describing FDG-uptake (k-parameters) have been estimated. These 
parameters represent some of the physiological conditions in the tumor; uptake and 
metabolism of glucose. For the CWR22 dataset, comparison of the mean k-parameters 
(treated tumors against untreated) yielded p-values of 0.06 for k1, the p-value 0.04 for k2 and 
the p-value 0.14 for k3. For the second dataset (MAS 98.12 against MAS 98.06) the same 
test yielded for k1 the p-value 0.06, for k2 the p-value 0.92 and for k3 the p-value << 0.01. By 
investigating every percentile of the parameter and testing, eve lower p-values could in some 
cases be found.  
By combining these parameters, an estimate of the metabolic rate of glucose (MRglc) 
can be obtained. The results showed that the treated CWR22 tumors were more metabolic 
active than the controls. We also found that the MAS 98.06 tumors had a higher metabolic 
rate of glucose than the MAS 98.12. Patlak plots can be used to calculate the MRglc as well 
and showed similar results; for the first data set a p-value << 0.01. For the second data set a 
p-value << 0.01 was found.  
This study demonstrate that both by looking at the tumor as a whole and investigating 
the heterogeneity it might be possible to distinguish different tumors from one another using 
dynamic FDG-PET .  
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1 Introduction 
In Norway, about 1/3 of total deaths are caused by cancer. For people aged between 45 and 
74 years of age, cancer is the most common cause of death. Still, the actual chance of dying 
from cancer is reduced since 1997. (1)  
Cancer is developed from cells that have lost the ability to control their cell division 
and self-elimination mechanics (apoptosis). The cancer cells will therefore multiply rapidly 
and a large lump of cells (tumor) will eventually be formed. Some tumors stop their growth 
when they reach physical limitations and are characterized as benign. Other tumors however 
will invade surrounding tissue and are characterized as malign. In order to maintain growth 
the tumor need blood vessels for nutrition and oxygen. They have therefore the ability to 
provoke angiogenesis, the recruitment of new blood vessels. With a makeshift blood network 
the tumor will be able to grow larger, and will also have a way of spreading to other regions 
of the body. The phenomenon is called metastasis and is a major challenge in cancer 
treatment. (2) 
There are several different ways of treating cancer, and radiotherapy is one of them. 
The discovery of x-rays in 1895 by Wilhelm Röntgen and the discoveries of radium and 
polonium by Marie Curie was the beginning of radiotherapy. Thus radiotherapy of cancer has 
been present for more than 100 years. At first radium was mainly used for treatment, 
followed by cobalt and cesium units in the 1950s. The medical linear accelerators have been 
in use since the 1940s and are the standard in modern clinics. (3) Other treatment methods 
include brachytherapy which is radioactive metals placed inside or close to the tumors. 
Chemo and hormone therapy is other methods where medicinal drugs are involved. Surgery 
is still the most used method for treating cancer. All these modalities have strengths and 
weaknesses, but they can be combined for more effective treatment. For instance, external 
radiotherapy may be given after surgery to deal with possible residual disease.  
The development of modern imaging techniques like computed tomography, nuclear 
magnetic resonance imaging and positron emission tomography (PET) have contributed to 
better treatment planning and tumor delineation in radiotherapy. PET is a diagnostic imaging 
technique that have several different applications regarding cancer. It can be used to find 
tumors in the body, especially useful if there is a chance that a primary tumor discovered has 
spread to different locations. Furthermore, PET may be used to help distinguish malign 
tissue from benign tissue and define the stage of the disease. Also, PET may aid further 
characterization of tumors, which can be used to identify radioresistant regions within tumors 
in need of elevated radiation doses, and then monitoring response of the therapy. After 
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ended therapy PET can be used to examine the any remains of the tumor and evaluate the 
chance of successful treatment.  
Apart from cancer, PET is used for several studies of the brain; it can be used to 
examine patients suffering from epilepsy, mapping of damaged tissue due to Parkinson’s 
disease and it is a useful tool for finding early signs of dementia. (4) 
The basic principle of PET is the use of a positron emitter attached to a tracer 
molecule. The tracer is injected into, and thus distributed within, the patient. Normally, after 
around 1 hour, the patient is ready for examination. The PET machine consists of a ring of 
detectors, all facing the centre. When the radioactive material inside the patient decays, it 
emits positrons. The positrons will very quickly interact with an electron, resulting in a 
subatomic explosion, sending off two photons in opposite directions. If both of these photons 
manage to escape the body of the patient, they might interact with the surrounding ring of 
photon detectors. A computer will log the time of event and what pair of detectors that 
registered the event. The data is stored in a matrix called a sinogram. Several different 
techniques can be applied to reconstruct the images and produce a representation of where 
all events occurred. (5)  
1.1 Motivation and goals 
As cancer is a disease that is different from patient to patient in biological 
characteristics, it is important to learn about factors that e.g. determine treatment outcome. 
To date, biopsy is a common way to investigate a given tumor. But it is known that tumors 
display heterogeneity, thus a few sample cells might not be enough to give a complete 
understanding of the entire tumor. Tumor treatment response is also a variable across 
patients. If this can be assessed early it will be possible to adjust the treatment plan 
accordingly. In this work, tumor information from dynamic FDG-PET imaging was investiated, 
both for assessing radiation response and for characterizing different tumors in mice.  
3 
 
2 Background 
2.1 Basic principles 
2.1.1 Photon interactions 
For the purpose of radiotherapy and PET imaging, one must be familiar with the basic 
physics governing the movements of photons through matter. That the photons interact with 
matter and deposits energy is the crucial point in radiotherapy. In PET the most important 
part is to construct efficient photon detectors.  
There is several different ways a photon can interact with matter; photoelectric effect, 
Rayleigh or Compton scattering and Pair production. The chance of interaction is determined 
by the energy of the photon and the density (or effective atom number) of the medium it is 
traversing. Below in Figure 1 is a graph describing the relative probability of the different 
interactions. 
 
  
Figure 1: Photon interactions dependent on photon energy (courtesy of University of Toronto, Ca). 
As shown above, the photoelectric effect is dominant for low energies. The entire 
photon can be absorbed by an electron, which escapes the atom/molecule it was bound to. 
The molecule will end up in an energetically unstable state., and may rearrange its electrons 
and emit characteristic radiation in form of a new photon.  
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If the photon is subject to Rayleigh scattering it will change its direction but retain all 
its energy. When undergoing Compton scattering however, it will interact with a free electron 
and give it considerable energy. Because of this the photon itself will lose energy and change 
its direction. As momentum and energy is conserved during such an elastic collision, there 
exist a relationship between the energy and scattering angle of the new photon; 
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2
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cm
E
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where E is the energy of the original photon, Esc energy of the scattered photon, c the speed 
of light, me the mass of electron and θ the scattering angle.  
Finally, in pair production a high energy photon (minimum energy 1.022 MeV) 
interacts with a nucleus and produces a pair consisting of an electron and a positron. These 
particles will mainly be spread forward in the direction the photon was heading. (6) 
2.2 Equipment of Radiotherapy 
2.2.1 The linear accelerator 
As photons from an ordinary X-ray tube does not have enough energy to efficiently reach 
deep into tissue, a new type of machine had to be developed in order to produce higher 
energy photons. The linear accelerator (linac) can produce electrons with energy of more 
than 20MeV, where the electrons gain energy by interacting with a synchronized radio-
frequency electromagnetic field. The electrons originate from an electron gun and then 
moves into a long tube, the accelerating waveguide. Inside this tube, the electrons ‘surf’ on 
the microwaves and gain more and more speed. The tube is usually too long to practically 
point down towards to the patient, and a bending magnet is thus applied to change the 
direction of the electrons. The electrons themselves can be used for therapy, or they can 
bombard a target to form high energy x-rays. It should be noted that the x-rays generated 
from this machine will have a spectrum of energies. The x-rays will then be shaped into an 
uniform treatment field of selected size. If the linac got a multileaf collimator (MLC) as well, 
the field can be shaped to better fit the extent of the tumor. Dosimeters are placed in the 
head of the linac in order to measure the treatment dose. (7) An illustration of the linac is 
shown in Figure 2.  
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Figure 2: Schematic diagram of a linear accelerator designed for radiotherapy used in x-ray mode. (7) 
 
2.2.2 The cobalt machine 
As opposed to the intricate design of the linear accelerator, cobalt machines are fairly simple. 
The radiation comes from a radioactive source emitting high energy gamma rays (and some 
low energy beta rays). The energy of the photons is mostly monochromatic and is either 
1,173 MeV or 1,333 MeV. The source is placed in the head of the unit which must be able to 
shield the surroundings from the source and make sure the beam is collimated to the correct 
size. As the radiation from this machine is always “on”, safety measures to avoid radiant 
contamination must be strict. 
2.3 Positron emission tomography 
Positron emission tomography is a relative new imaging modality and came into use in the 
1980s. The basic principle is a radioactive tracer that emits positrons, a ring detector that can 
catch the annihilation photon pairs and electronics to make sense of it. The following chapter 
will review some of these aspects. In Figure 3 the basic PET setup is displayed.  
Most of the information in this chapter is based upon the work of Michael E. Phelps (5). 
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Figure 3: The basic steps in order to produce a complete PET image (Wikipedia).   
2.3.1 Tracers 
The tracer in PET consists of two equally important parts. The first part is a to select a 
suitable molecule that is incorporated by the cells in the human body, a tracer. A PET survey 
will show you the distribution of this tracer in the body. To monitor metabolic activity for 
instance, glucose (or glucose analogues) can be used. The next task is to find a radioactive 
isotope that can be attached to the molecule without changing its properties too much. This 
can be done by removing a small group of atoms and replace it with an isotope with similar 
atomic weight and electron structure. It is vital that the body can still recognize and use the 
molecule as if it was of original structure. The isotope should primarily emit positrons. All 
other radiation emitted would be useless for the survey and also irradiate the patient. It is 
also important to consider the physical and biological half time of the isotope. If the half time 
is very short, a lot of the activity would be spent on the way from cyclotron (see below) to the 
patient. If it is too long, little activity would be shown when imaging the patient. For example, 
18F has a half time of 110 minutes, which is considered to be quite suitable for the purpose of 
PET. 
7 
 
The glucose analogue 2- deoxy -2 -[18F]-fluoro-D-glucose (FDG for short) is a 
molecule that can be used to look for cancerous growth as it monitors metabolic activity. The 
isotope 18F is produced from 18O -water that is bombarded by 16MeV protons from a 
cyclotron. Synthesis of the complete molecule is performed according to the routines 
presented in the article by Joanna S. Fowler and Tatsuo Ido. (8). In  a model of the molecule 
and where the 18F atom has replaced an OH group compared to glucose is shown. 
 
Figure 4: A representation of the FDG molecule (Wikipedia) 
As will be shown there is also a high metabolic activity in the brain, kidneys, and 
intestines. The bladder will also accumulate FDG. Therefore other tracers / methods might 
be considered to look for cancer in these regions. But if one wait for about 3 hours after 
injection, it might still be possible to distinguish tumors here. When 18F decays, it turns into a 
heavy oxygen atom with negative charge, which quickly attracts a positive hydrogen core. 
This new molecule is harmless and can in normal cells be used for further metabolism. (9). 
FDG is the most commonly used PET tracer, and is used in more than 90% of all surveys 
worldwide and exclusively in Norway (4).  
 
 
2.3.2 The tracer in the body 
The tracer (FDG) is intravenously injected into the patient and will be transported in the blood 
stream as normal glucose. When the FDG reach the capillary blood vessels, it will leave the 
blood and move into the space in between the cells. GLUT transporters help pulling the 
tracer into the cells. An illustration of this is given in Figure 5.  
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Figure 5: Transportation of glucose and FDG across the cell membrane (Wikipedia). 
When FDG enters the cell, it may undergo glycolysis. The first step is phosphorylation 
by hexokinase and ATP, and this reaction is illustrated in Figure 6. However, the fluor atom 
stops further metabolism of the molecule. Thus the FDG will remain inside cells for a longer 
time. This attribute is very much desired for the imaging process. 
 
Figure 6: The phosphorylation reaction of glucose (Wikipedia). Note that for FDG the second OH 
group is replaced by 18F. 
2.3.3 Annihilation 
18F atoms will emit positrons and revert to 18O. This will subsequently cause annihilation of a 
positron and electron which will result in two high energy photons. An assumption is made 
that the positron annihilate at the site of FDG, and that the photons produced travel in exact 
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opposite directions. This is not exactly true. The positron emitted from a radioactive nuclide 
will have a component of kinetic energy. The positron is therefore able to travel for a certain 
distance before it interacts with an electron. The probability of interaction is inversely 
dependent on the speed, and it is intuitive that positrons of higher energy will travel for 
longer. It follows that the distance is dependent on the radionuclide used for a PET. For 18F 
the maximum energy an emitted positron can possess is 635 keV. This is relative small 
compared to other radionuclides used. The distribution function for the distance traveled 
have a full with half maximum (FWHM) of 0.1 mm and full width tenth maximum (FWTM) of 
1.0 mm. This means that most of the positrons travel less than a millimeter, but they can 
travel further. This effect cause image blurring and limit the spatial resolution that could 
theoretically be possible for PET. Strong magnetic fields can reduce these effects (10) but is 
not practical to implement.  
Another problem is that both the positron and the electron interacting have a bit of 
kinetic energy, and therefore the scatter angle between the resulting photons is not exactly 
180o. It will instead be a roughly Gaussian shaped distribution around 180 o with a FWHM of 
about 0.5o. The blurring due to this effect can be estimated as: 
Dnc  0022.0  
Where D is the diameter of the PET scanner. For the moment these effects are relative small 
compared to the typical resolution of a clinical PET scanner. An illustration of these effects is 
provided in Figure 7. The problem of photon interactions within the body is discussed later in 
chapter 2.3.5. 
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Figure 7: Illustration of errors due to positron range and non-colinearity. (5) 
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2.3.4 Photon detectors used for PET 
The detectors are a vital part of the PET scanner and need to have several specified 
properties. They need to be able to efficiently detect photons with energy of 511 keV and it is 
also useful if they can detect the actual energy of the incoming photons. If so, scattered 
photons can be discarded. A precise measurement of the spatial location of the interaction 
improves the spatial resolution of the images. The ability to determine when the photons hit 
the detector is crucial in order to pair photons that spawned from the same interaction. 
Scintillation detectors are used for most present PET scanners. They consist of a dense 
crystalline scintillator material where photons interact. When a photon interacts with this kind 
of material visible light is emitted. This light can then be recorded as an electrical current at 
the end of a photomultiplier tube (PMT). See Figure 8 for an illustration of this setup. 
 
 
Figure 8: The basic components of a scintillation detector. (5) 
Scintillators will emit light in the visible spectrum when high-energy photons deposit 
their energy in them. They are therefore transparent and dense, allowing the light a chance 
to escape and increasing the chance of interaction with high-energy photons. The amount of 
light emitted is proportional to the energy deposited in the scintillator. However, the light is 
emitted equally in all directions, so not all reach the second photon detector. Even though a 
single high-energy photon causes the emission of a wave of lower energy photons, only one 
electric pulse is recorded. The amplitude of the pulse will be related to the energy of the 
interacting photon. Because of this it is possible to reject low energy photons that have been 
scattered in the body. 
For PET imaging dense, inorganic solid scintillators are chosen. Even the materials 
with high stopping power must be several centimeters thick in order to efficiently stop a larger 
percentage of incoming photons. The stopping power is therefore a major factor when 
considering different scintillators. “The brightness of the scintillator (the number of light 
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photons produced per 511 keV interaction) is important because the integrated light signal 
from the scintillator is used in several different ways. In many detectors, the relative 
amplitudes of the signals seen by adjacent light sensors viewing a piece of scintillator are 
used to determine the location of the interaction.” Unfortunately, not all the light photons are 
detected. This causes fluctuations in the output which are governed by Poisson counting 
statistics.  
Accurate measurements of when photons interact with the scintillator are important 
because of the coincident detection of the two annihilation photons. The accuracy of timing is 
dependant on the decay time of the scintillator and its brightness. “A fast, bright scintillator 
will produce a signal with less timing variation than a slow, dim scintillator.”  
Most PET scanners use photomultiplier tubes (PMT) as the photon detector to 
convert scintillation light into an electrical pulse. At the entrance of the tube, a photocathode 
is placed. When a light hits the cathode, a loose electron will be given enough energy to 
launch itself off the cathode. It will then be directed towards a positively charged electrode, 
called a dynode. The electric potential difference will give it enough speed to bounce off the 
electrode and head towards the next dynode. Each time the electron bounce off a dynode, it 
knocks off 3-4 other electrons as well. This will rapidly increase the number of loose 
electrons that will finally strike an anode at the end of the tube. This will cause an electric 
current which is the new output signal. Se Figure 9for an illustration of a PMT.  
 
 
Figure 9: A schematic of the basic photomultiplier tube. (5) 
Some of the PMT models available are multichanneled and position sensitive. Still, 
most PET scanners use single-channel PMTs with sizes ranging from 1 to 5 cm in diameter. 
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“The advantages of MPTs are their high gain, which leads to high signal-to-noise pulses, 
their stability and ruggedness, and their fast response. “ 
By arranging scintillator crystals and PMTs together, a block detector can be created. 
This design was proposed by Casey and Nutt (11), and the majority of PET scanners use 
this design. This consists of a relatively large block of scintillator material (typically 4 x 4 cm 
in area and 3 cm deep). This block got cuts filled with reflective material to make it into a say 
8 x 8 array of detector elements. This is then attached to four PMTs, see Figure 10 
 
 
Figure 10: The design of the block detector. (5) 
The depth of the cuts varies across the block in order to share the light between the 
PMTs. As illustrated, in the middle, the cuts are shallow, allowing all PMTs light. Thus one 
can determine the actual entrance in the 8x8 array by looking at the relative light in the four 
PMTs. By doing this one catches two flies in one go. This reduces the number of expensive 
PMTs used and the spatial resolution can be improved to a certain level. 
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2.3.5 Coincidence detection 
In PET, coincidence detection is used rather than absorptive collimation to determine the 
location of the emitted photons. The basic principle is that when an annihilation event occurs, 
two photons will be emitted in opposite directions. If both are caught by the detectors, the 
event will be recorded. It is then assumed that the event occurred somewhere along the line 
that goes from one detector to the other. The detector pair and time of event is stored for 
each accepted coincidence. Under ideal circumstances the photons hits the detectors 
simultaneously, but this is not always the case. Therefore a time window in which two 
occurrences can be recorded as a pair is in place. This window depends on the scintillator 
material used and is mainly in the order of a few nanoseconds. If the window is too big 
however, the chance of recording another random event increases. This will lead to false 
coincidences. The different types of coincidences that might occur are described in the 
picture below.  
 
 
Figure 11: The situations that might be recorded as events. (5) 
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The scattered coincidences cause a displacement of the actual event. The fraction of 
these events can range from 15% to over 50% of the total data and are also the most difficult 
to correct for. The random coincidences cause worse errors and form a background noise 
that should be removed whenever possible. The rate NR of these occurrences can be 
calculated; 
 212 NNNR   
Where τ is the width of the logic pulses produced when a photon is absorbed in the 
detector (2τ is the usual coincidence timing window.) N1,2 are the individual photon detection 
rates in a pair of detectors. When more than two photons are recorded simultaneously they 
are usually discarded, but in some circumstances it is considered better to choose a random 
pairing instead. 
2.3.6 The sinogram 
“A simple Pet-system consisting of 32 individual detectors in a ring, scanning an object with a 
2-Ddistribution of radioactivity denoted by a(x,y) (Figure 12).  
 
 
Figure 12: A simple 2D detector system with numbered detectors. (5) 
 
The raw data, which consists of the detection of annihilation photon pairs, usually is 
histogrammed into a 2-D matrix, where each element in the matrix corresponds to the 
number of events recorded by a particular pair of detectors (or along a specific line of 
response). The matrix is arranged such that each row represents parallel line integrals or a 
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projection of the activity at a particular angle ϕ. Each column represents the radial offset from 
the center of the scanner, r. The relationship that relates which elements in this matrix (r,ϕ) 
record data from radioactivity in the object at location (x,y) is given by: 
 sincos yxr   
This 2-D matrix s(r,ϕ) (see Figure 13) is known as a sinogram because a point source 
located at a location (x,y) traces a sinusoidal path in the matrix as given by the above 
equation.” (5)  
 
 
Figure 13: The sinogram, each entry represent a detector pair and the events in that pair will be 
recorded in that entry. (5) 
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Figure 14: Illustration of how an object will appear in the sinogram. (5) 
2.3.7 Image reconstruction 
Image reconstruction is needed in order to obtain an image that looks like the object imaged. 
One of the techniques is iterative reconstruction. A flowchart of this method is shown in 
Figure 15. An estimate of the original object will be made and then forward projected in order 
to obtain a sinogram. This sinogram is then compared to the sinogram recorded from the 
PET assay. If the likeness is not good enough, it will be rejected and try again until it 
converge.  
 
Figure 15: Flowchart of the iterative image reconstruction technique. (5) 
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2.3.8 Radiation dose to patients 
If one are concerned about the radiation damage to the patient from this kind of survey, the 
effective dose for a PET survey (using FDG) have been calculated to 0.027mSv/MBq [ICRP]. 
The activity used in surveys range from 100-370 MBq. Others work with a bit larger number, 
0.0299 mSv/MBq and using 370MBq, giving a total effective dose of about 11mSv. These 
dose values are close to the ones obtained from a CT scan. There is also worth mentioning 
that as the FDG is not evenly distributed some organs (like the bladder) will receive larger 
doses. (12) As for how the radioactivity leaves the body; 20% is excreted through the renal 
system while the rest stays to decay. The patient will therefore emit a heightened level of 
photons for about 12-24 hours after a survey. (13) 
2.4 Pharmacokinetics 
After acquiring PET data, we will try to put it into a model to describe the system; this is 
called tracer kinetic modeling. These models are very similar to pharmacokinetic models, the 
main difference is that the doses used are smaller (a tracer). Instead of introducing a drug 
that is supposed to affect the system, the tracer should ideally pass through without making 
any disturbance. There are three different kinds of tracer kinetic models; noncompartmental, 
compartmental and distributive. For PET analysis, the compartmental model is preferred by 
most. This is because “they are simpler to implement and often prove adequate parameter 
estimates”. Another trait of these models is that they “look” like what we are studying; 
different compartments for the different states of the tracer. One thing to note about the term 
compartment in this context is that it isn’t necessary a physical defined volume. Shown below 
is the system used for this study, as you see we have one compartment for FDG in tissue 
and one for FDG 6-P (metabolized FDG) in tissue, where both molecules are within the same 
cells. 
 
 
Figure 16: Three Compartment model for FDG in vivo. 
The arrows in the model represent the movement of tracer between the 
compartments. These movements are decided by the interconnections across the 
compartments. These interconnections are linear if they are not dependant on tracer mass or 
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time, but they can vary across the tissue itself. Even though the biological processes we look 
at are in general non-linear, a linear model can in some cases still be used. In several 
studies you can obtain data by applying a small trace dose and observing the dynamics. 
“Such test signals give rise to very small perturbations about the operation point, so the 
dynamic equations describing experimental perturbations are linear even though the intrinsic 
dynamics of such a system may be nonlinear” (14).  The main reason for this is that the 
mass of the trace dose is much less than the mass of molecules it resembles. Specifically, it 
has been shown (15) that when glucose metabolism is in steady state, the tracer system is 
linear. An important physical property of the tracer kinetic model is the mass balance. This 
means that the measured change of mass in a compartment must result from the amount of 
tracer coming into the compartment, minus the amount leaving it. In a dynamic PET series 
we can measure these variables over time, and find the rate of mass exchange. In this study, 
our equations consider the mass balance of the compartments, rather then the concentration 
of tracer. A complete set of equations like these are often called state equations. 
2.4.1 Two-tissue compartment model 
In this section a model that is commonly used to describe the uptake and retention of FDG is 
presented. (16) We define the following: 
CP (pmol/ml) is the molar concentration of tracer in the plasma 
CF (pmol/ml) is the molar concentration of unbound tracer 
CB (pmol/ml) is the molar concentration of metabolized or bound tracer.  
The kinetic parameters k1, k2, k3, and k4 give the rate of tracer exchange between 
the compartments. k3 is an apparent first-order rate constant, while the rest is true first-order 
rate constants.  
Cp(t) is assumed to be known and identical for all voxels. The other parameters will 
vary for each voxel location, s. Considering mass balance and blood fraction (bf) we want to 
solve for the following equations; 
bftsCtsCtsCtsC FBFT  ),(),(),(),(  
Where CT is the activity measured in the voxel.  
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The solution to these is shown below 
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3 Experimental setup and procedures 
3.1 The use of mice for this project 
Mice have been used for this project. They have all received implants of human tumor 
xenografts. Ten mice with CWR22, six with MAS 98.12 and five with MAS 98.06. A brief 
description of these tumors is given in chapter 3.2. Half of the mice with CWR22 received 
radiotherapy. Later PET assays were done on all mice, comparing treated against controlled 
mice with CWR22 and MAS 98.12 against MAS98.06. A detailed description of the mice and 
their habitat is found in the appendix. 
3.1.1 On the use of animals and the animal model 
Once the decision of using animals for an experiment has been made, several aspects must 
be addressed. Concerning animal welfare, a rule of thumb called “the three R’s” has been 
constructed  
*Reduction – Reduce the number of animals used  
*Refinement - Refine the methods, models and environment 
*Replacement - Replace in vivo research with in vitro research where this is possible 
In general, animal experiments are used to answer questions in biology and medicine 
related to human or animal health. It has been shown that several biological processes in the 
body are similar across different species. In this study, mice have been utilized to gain 
knowledge about human cancers. In most cases, a specific drug or treatment will have the 
same effect on all species. The differences that do exist however can in some cases be used 
to an advantage in specialized research. One must also keep in mind that the dose given will 
not have the same effect on different sized animals. For instance, small rodents can endure 
more radiation than humans. For our PET study, we are mostly concerned about the 
metabolic processes. These processes are very much the same in most life forms wherever 
they are on the ladder of evolution. There are also differences between animals of the same 
species. So in order to get reproducible results and results that can be properly compared to 
other work, one should make sure to choose a specific strain of a specific species of animals.  
After considering all the things concerning the animals used, we must now consider 
the effects of the environment they are kept in. Everything from the temperature to the 
bedding can cause differences so all animals should be treated equal. Most importantly, one 
must ensure that the animals are treated properly. Having stressed animals is ethically 
unacceptable and it will also affect the experiment. To ensure that the work done can later be 
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compared to other work, as much information about the above points should be recorded 
and presented with the work. (17) 
3.1.2 Implantation of tumors 
Prior to the tumor implantation, the mice were anesthetised by subcutaneous injections of 
“Zoletil Mix”. This mixture is made of 2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam (Zoletil 
vet, Virbac Laboratories, Carros, France), 3.8 mg/ml xylazine (Narcoxyl vet, Roche, Basel, 
Switzerland), and 0.1 mg/ml butorphanol (Torbugesic, Fort Dodge Laboratories, Fort Dodge 
IA), diluted 1:5 in sterile water. The dose given was 50 µl/10 g of body weight. While waiting 
for the mice to fall asleep, tumors (human androgen-sensitive CWR22 xenografts) extracted 
from other mice were prepared. These tumors were cut into small cubes with sides of approx 
1.3 mm length. Before operating, an area of skin was cleaned using alcohol. A one cm long 
cut was made on the back of the mice, and then tweezers were used to make small pockets 
under the skin. The tumors were then inserted into these pockets near the flanks. The wound 
was then glued together with histoacryl. Finally, a salve was applied to the eyes of the mice 
to prevent damage. This is because mice can’t close their eyelids when knocked out. The 
last remaining thing to do was to mark the mice. This was done using scissors and a special 
pincer to make triangular or circular cuts in their ears. When this procedure was complete for 
a group of mice, they were put back in the cage. They were here placed huddled together 
and covered with some of the bedding to prevent severe heat loss. Then the cages were 
labelled with a project nr and a note telling which mice are inside before being returned to 
their housing unit. A humane endpoint for the mice has been established. If the tumors grow 
to a size that will hinder the animal’s movement, they will be euthanized. As will all the 
animals in the end of this experiment. 
3.1.3 Irradiation 
One day before the PET assay, all cages were brought down to the irradiation lab. This was 
for two reasons; first to ensure that all mice receive a handling that is as similar as possible. 
Secondly, there were some mice to be irradiated from each cage. Each cage contained 
some mice from both groups. This is because the micro environment within each cage can 
be different, and we don’t want it to affect only one group. In correspondence to what was 
stated above, all mice were anesthetized. The mice were anesthetized cage by cage with the 
same method used as when implanting tumors. When the mice were knocked out, groups of 
four would be irradiated at the same time. They were placed upon a sheet with a 10 by 10 
cm square drawn upon it, (the same size as the radiation field). The tumors were placed at 
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the corners of this square and the rest of the body located as far from the centre as possible 
(see Figure 17). After making sure the sheet was placed correctly under the beam, a 5 mm 
thick layer of polystyrene was laid on top of the mice. This layer was supported by small 
pieces of cardboard to ensure the mice wouldn’t be crushed. The function of this layer was to 
create a dose buildup for greater effect in the tumor, as the millimeter of mouse skin is not 
enough to provide this. The source of radiation used was 60Co (Mobaltron 80, TEM 
Instruments, Crawley, UK) with a dose rate of 0.8 Gy/min. This source gives off radiation in 
the form of gamma rays in the megavolt range. The dose given was 7.5 Gy. After irradiation, 
the mice were placed back into their respective cages. They were again placed huddled 
together for warmth. Then the cages were taken back to the animal stall. 
 
Figure 17: Setup for mice in the radiation field. 
3.1.4 PET assay 
The following day, the mice were transported to Rikshospitalet where the small PET scanner 
is located. This scanner is a microPET Focus 120, (Siemens Medical Solutions, Erlangen, 
Germany). A performance test of this device has been done by other scientists (18). Again 
the work began by administrating the anesthetic, but this time only on two mice at a time. 
The knocked out mice were placed in the PET scanner atop a cushion, with a heat lamp 
directed towards them. As they were about to be subjected to an hour long PET assay they 
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needed this to conserve sufficient body heat. Then a 10min transmission scan with a 68Ge 
point source was performed to obtain data for attenuation and scatter correction. Activity of 
the tracer was measured, and doses of 10-15 MBq 18F-labelled FDG (GE Healthcare AS, 
Oslo, Norway) in heparinized saline were prepared. These were carefully administrated into 
the venous vein of the tail. This was done on the first mouse in the same instant as the data 
acquisition began. Both mice had a needle already in place to make sure the dose for the 
second mouse could follow quickly. When the first pair had been in for some time, the 
second pair was anesthetized and prepared.  
To ensure good FDG uptake, the mice have been denied food for 10 hours. The 
hungry and awake companions in the cage are prone to nibble on knocked out and 
defenseless mice. Therefore the pairs finished with the assay were not immediately placed 
back into their cage. Instead they were placed on top of surgical gloves filled with heated 
water. When they eventually showed signs of restored vitality they were put back in the cage. 
This process was repeated until the end of the day and continued on the next day.  
Later 4D emission data were reconstructed using OSEM-MAP (2 OSEM iterations, 18 
MAP iterations, b_0.5, matrix size_128_128_95 (19), (20), producing images with a voxel 
size of 0.87_0.87_0.80 mm3. The reconstructed time frames were 10 s during the initial 5 
minutes, and the following time frames were 30 s.  
3.2 The tumors used 
3.2.1 CWR22 
This tumor is an androgen-dependent xenograft model that is made from a primary human 
prostatic carcinoma (PCA). It was done by Pretlow TG et. al. (21) and several of these 
researchers have investigated the tumor line. They describe CWR22 as “having 
characteristics that suggest that it is exceptional among the currently available models for the 
study of human PCA. We believe that the general availability of this xenograft will offer a 
unique opportunity for the investigation of experimental therapy and the control of growth in 
PCA” (22). 
3.2.2 MAS 98.12 and MAS 98.06 
These are two different breast cancer xenografts with quite different properties. The luminal-
like MAS 98.06 showed positive staining for estrogen receptor (ER). This is a protein which is 
a favorable prognostic marker. The basal-like MAS 98.12 however, did not show signs of ER. 
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The MAS 98.06 got more proliferation genes than the MAS 98.12 line (23). It might then be 
possible to identify them by looking at the metabolic rate of glucose, as this can be a sign of 
proliferation. 
3.3 Non-linear curve fitting 
The first curve fitted is the plasma function. For use in the pharmakokinetic modeling it is 
handy if the plasma function is expressed as a exponential function on the form described 
belov. 
dtbt
P eceaC
   
where t is the time, and the others are parameters that will be fitted to the curve. To fit the 
function to the data, a non-linear regression algorithm has been used. The IDL algorithm for 
this was developed by Craig Markwardt (24). It is based upon the Levenberg-Marquardt 
techniqe where a least squares regression is done. In order to adapt the model to fit the 
measurements, the parameters are regulated by minimalizing the sum of of the squares of 
the deviation between the measured time activity curve of plasma (TACP) and the fitted 
model. This sum is given by 
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where CP(ti,par) is the value estimated from the model, par is the vector containg the 
estimated parameters and Wi is the weight of each residiual. Each residual is weighted with 
the inverse of the standrad deviation of the corresponding datapoint in the measured TACP  
(25). The initial value of the parameters a,b,c,d had to be manually chosen, and if they are 
way of target, the algorithm might fail. Constrains for the parameters could be set aswell, but 
was not used for the plasma function. The models t=0 was set to when the TACP reach its 
peak. The final plasmafunction was therefore a combination of the fitted model, and erly 
TACP values.  
The tumor model described in chapter 2.4.1; 
bftsCtsCtsCtsC PBFT *),(),(),(),(   
was fitted with the same algorigthm. Here the parameters was limited to positive values.  
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3.4 Image and data handling by the use of IDL 
This section is about IDL sequences (program) that have been developed to get useful 
information out of PET-images. When this program is run from the beginning to the end, it 
should have collected all data needed from one tumor. The plasma function, the tumor 
region, the free and bound functions and the k-parameters. This data is saved both in 
graphic for your eyes and in IDL save files for later use.  
It starts with reading image information from Dicom files and go all the way to usable 
output. All this is done without changing the source code in between sets of images. By 
prompting the user to answer questions, enter settings in the command line and using while-
loops that don’t stop before you got what you want, this has been more or less achieved.  
Starting with something simple, a method for just looking at the pictures in order was 
developed. For example how one slice would change in time, or go through the entire animal, 
slice by slice, at a given time. For the moment these two types of visualization is available for 
coronal slices only. Displayed below in Figure 18 is a time dependant series, the image 
scaling have been optimized to look for the tumor in this mouse. 
 
 
Figure 18: Coronal slice of tumor section and whole mouse. The time after injection of FDG is shown. 
Note that this picture has been rotated 180 degrees relative to the original.  
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As you can see the tumor is growing more and more visible as the time increases, as 
it accumulates more and more FDG. Heterogeneity within the tumor is also clearly visible in 
these images and you can see that the region in the middle of the tumor is getting its FDG 
last. It is very nice that it is possible to visualize this, as it is important to know about the 
different parts of the tumor and not just the average. But it is not enough to just see these 
images with the eyes, we need to collect data from each voxel within the tumor and analyze 
this more thoroughly. This can for example be done by looking at histograms and percentile 
values. Methods for doing this are described later.  
The first thing you will have to do when starting the program is to choose which 
mouse you want to collect data from. A full image is displayed, showing all mice in the 
scanner. Imagine a small box containing just one mouse (see Figure 19). By clicking the 
bottom left corner and then the upper right corner of this box, this selection will be mapped 
onto a new array that fits it size, while the rest of the data will be rejected. By doing this, two 
things have been accomplished. First, the storage space required and RAM usage has been 
reduced to about 10%. Secondly, now only one mouse will be displayed, and therefore the 
scaling of images will be individual for that mouse.  
 
Figure 19: To choose which mouse to work on.  
The first thing we need for our model is to determine the arterial input function, i.e. 
information about the FDG concentration in blood. As it can be quite difficult to look for an 
artery in small animals like mice, we rather try to find the left heart chamber where we can 
extract this information. This procedure in the program would also be able to collect data 
from any chosen voxel in the image (for example arteries in larger animals). Now, to do this 
we need to find the heart, which is not always an easy task. Sometimes you will get images 
that look like the left part of Figure 20. By clicking a random voxel, and then rejecting this as 
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your wanted voxel when the program prompts you, you will be able to choose new ways of 
displaying the image (you should get a message about the default scaling used). Image 
scaling and time interval is therefore adjustable. By trying and failing it will sometimes be 
possible to get an image like the one shown at the right hand side of Figure 20. 
 
 
Figure 20: Heart slice with bad scaling on the left and optimized scaling on the right (both from the 
same mouse)  
It is not always possible to get as nice images like this, but by making some educated 
guesses at the location of the heart one can still find voxels that might do. From these voxels 
reasonable functions can still be found.  
When finally accepting the chosen voxel / location, the program runs on an autopilot if 
you use the default settings. In the end it should give you a few sample intensity functions 
from some voxels, and the averaged result that will be used in the end. Unfortunately it is not 
before this point you can be absolutely sure you got a reasonable function, and as it is now, 
you would have to force the program to stop and start over in order to look for a better 
function. 
The next thing to do is find the tumor and then draw a region around it to define the 
location for the program. Again the program will start with showing you some pictures, 
helping you to pin point two of the tumor edges (in the z-plane). Be sure to click below the 
centre of the tumor when choosing its bottom edge, as these coordinates are later used to 
display k-maps of the tumor region. If the image is badly scaled, you should select a negative 
z-range to quickly be able to define new settings. When you’ve chosen the z-range, a series 
of x-y images will be shown, and all you got to do is delineate the tumor by tracing a region of 
interest (ROI) around the tumor. A nice image of this will look something like that displayed in 
Figure 21 below. 
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Figure 21: On the left, image to select the z range from. On the right, images to draw tumor ROIs in. 
The tumors seen here is the CWR22 xenografts. 
When you have finished drawing all the ROIs you will be prompted to answer whether 
you are satisfied or not. Are you not satisfied with the regions you drew, or maybe the scaling 
was too bad to do so in the first place, you will get some new options. You can rescale the 
images and you can also watch a little movie that goes through all xz-images (coronal) in the 
mouse. Watching this movie might be helpful if you’re having trouble finding the tumor. The 
y-value for each image will also be shown, and you can use a y-value from a good image to 
define the lower and upper values for z (also called z-range). Now we are back at the 
beginning and you can continue to try better scaling and drawing better ROIs until you are 
satisfied.  
Now you got both a heart function (arterial function) and the tumor region plugged into 
the program. This is all it needs to do the pharmacokinetic modelling and produce data. The 
code for this was handed down from my supervisor Eirik Malinen. After a series of iterations 
the best fit for the model is presented. Functions called “free” and “bound” is displayed and 
represent the amount of free FDG among the cells and the bound or metabolized FDG. See 
Figure 22 below for a sample tumor function. 
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Figure 22: Median Intensity functions of FDG in tumor. Solid line is total. Bound is striped, and Free is 
Dotted. The median k-parameters for this treated CWR22 tumor are shown.  
More importantly the program gives you “k-parameters” which represent the rate of 
physiological processes such as FDG uptake and metabolism in the tumor. And it is the 
distribution of these k-parameters within the tumor that we want to analyze later. Therefore at 
the end of this program, histograms of k-value distribution will be shown on the screen and 
then saved to disk. It is also interesting to see “k-value maps” of the tumor, basically a picture 
of the tumor with regard to k-value and not radioactive intensity. With a few more lines added 
to the program, a sort of 3D representation of this is displayed on a 2D computer screen. In 
fact, it’s just a lot of 2D images next to each other, but you can imagine them on top of each 
other. No colour bar to match the specific values is present, but the max and min values are 
displayed (as well as the mean value). Shown in Figure 23 is an example of these images. 
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Figure 23: Maps of the k-parameters within tumor region for an untreated CWR22 xenograft.  
To sum up, when this program is run from the beginning to the end, it should have 
collected all data needed from one tumor. The plasma function, the tumor region, the free 
and bound functions and the k-parameters. This data is saved both in graphic for your eyes 
and in IDL save files for later use.  
 
3.5 Metabolic rate of glucose and the Patlak plot 
Assuming that the system will eventually enter a steady state it is possible to find a measure 
of the metabolic rate of glucose (MRglc). Using the principles of competitive kinetics, a 
lumped constant (LC) is introduced to relate the behavior of the tracer FDG to glucose in 
order to obtain. 
LC
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Where CP is the plasma concentration of glucose and assumed to be in steady state. 
The k* ‘s is the parameters found be pharmacokinetic modeling. (5) 
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The equation for the lumped constant is 
*
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Where ø is the fraction (1-r) of glucose that is metabolized after phosphorlyation. Vm* 
and Vm are the maximum velocities and Km* and Km are the apparent Michaelis-Menten 
constants. And λ is the ratio between the factors of FDG and glucose. (26) 
The Patlak plot (see Figure 24 below) is obtained by plotting 
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and CE is free FDG and CM is bound FDG. (5) 
 
 
Figure 24: Patlak plot.  
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The slope of the end of the line should equal 
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and thus be linearly related to 
the metabolic rate of glucose. (5) This constant will be referred to as the MRglc for the 
remainder of the work, as the lumped constant is in most cases close to a constant (27), and 
that our CP is incomparable. The absolute values will not be correct, but the comparison 
between the groups will not suffer.  
3.6 Statistical methods 
3.6.1 Hypothesis testing and the students t-test.  
In statistics there is a way of assessing uncertainty through so-called p-values. If it is of 
interest to ascertain whether something is true (a), then a hypothesis expressing the opposite 
(b) is put forward. Then the chance for this hypothesis to be true is calculated, and if the 
chance for (b) is less than 5%, it seems highly probable that our initial assumption (a) is 
correct. (28).  
In this work, the students t-test implemented in Interactive Data Language (IDL) has 
been used. In this work it is important to be sure if two groups show different properties, and 
this test fits the description. For this test, two arrays of data are compared. The hypothesis is 
that the data of both arrays are drawn from the same distribution. The following is the 
description of the function given in the IDL help file. 
“The TM_TEST function computes the Student's T-statistic and the probability that 
two sample populations X and Y have significantly different means. X and Y may be of 
different lengths. The result is a two-element vector containing the T-statistic and its 
significance. The significance is a value in the interval [0.0, 1.0]; a small value (0.05 or 0.01) 
indicates that X and Y have significantly different means. The default assumption is that the 
data is drawn from populations with the same true variance. This type of test is often referred 
to as the t-means test. The T-statistic for sample populations x and y with means ` x and ` y 
is defined as:” 
 (29) 
The function returns the t-value and the p-value. 
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4 Results 
4.1 General investigations 
4.1.1 Illustrations of dynamic series 
For the MAS 98.12 set, a presentation of the PET images is shown in figure 25, depicting a 
time series for a whole mouse. A few samples of the total of 37 time frames have been 
selected. 
 
 
Figure 25: Illustration of a dynamic PET series of mouse with MAS 98.12 xenograft. The arrows 
indicates the location of the implanted tumors. 
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These images show high activity in the heart and then in the intestine at an early 
stage but the activity in these areas fade over time. Activity in the tumors can be seen across 
the entire series and does not fade significantly. It can also be seen that the brain and 
bladder accumulates more and more FDG over time. The early images are noisier because 
of the high temporal resolution.  
The full dynamic series of the heart (of 20 time points for this mouse) is shown in  
Figure 26.  The image series shows a rapid uptake that quickly decline as the bolus of FDG 
passes the heart.  
 
 
Figure 26: A dynamic FDG-PET series of the heart of CWR22 mouse. 
 
4.1.2 Plasma function 
The plasma function itself might be useful to investigate. Some plasma functions from 
different mice are shown in Figure 27. Although some differences can be seen, mostly due to 
differences in injected activity, these functions describe the same course as depicted in the 
images in Figure 26.  
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Figure 27: Plasma functions. The solid line is from a CWR22 Control, the Gray line is from a treated 
CWR22, the dotted line is MAS 98.12 and the dashed line is MAS 98.06. Note that these are from 
individual mice. 
4.1.3 Tumor curves 
In Figure 28, curves describing the uptake in a single tumor voxels of a CWR22 mouse is 
shown. As seen, FDG is rapidly accumulated before a plateau is reached. The k-parameters 
are displayed along with r-squared and the blood fraction. Here we can see how the 
measured tumor activity can be divided into three parts; free FDG, bound FDG and FDG in 
blood. The underlying characteristics of the free and bound component show that the plateau 
is a consequence of a decreasing free component and an increasing bound one. Also, there 
is a considerable heterogeneity in the uptake characteristics voxel-to-voxel. In Figure 29, 
curves for a full tumor are depicted. As can be seen, the tumor is not much different from the 
random voxel. The function is entirely different from the what is found in the heart though.  
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Figure 28: Tumor voxel uptake curves. The solid line represents the total fitted uptake curve. The 
dotted line represents free FDG and the dashed line bound FDG. The solid grey line at the bottom is 
activity from blood within the tumor. The diamonds are the raw data.  
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Figure 29: Full tumor uptake functions. The solid line represents the total uptake function. Dotted line 
represents free FDG and dashed line bound FDG. The solid grey line at the bottom is activity from 
blood within the tumor. The diamonds are the raw data.  
 
 
4.1.4 Distribution of pharmacokinetic parameters 
To illustrate tumor heterogeneity, the range of k-parameters across the voxels can visualized 
in histograms (figures 30-32). In the histograms the diversity within the tumor is displayed. 
The distribution seems fairly Gaussian but somewhat left-skewed for k3 in this tumor.  
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Figure 30: Histogram of k1 values for a CWR22 control tumor 
 
Figure 31: Histogram of the k2 values for a CWR22 control tumor.  
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Figure 32: Histogram of the k3 values for a CWR22 control tumor. 
 
In Figure 33, an area of tumor with high uptake has been compared to an area of low 
uptake. The difference between these curves is clear, and it seems like it is the bound FDG 
that makes the difference. In Figure 34, a map of the k-parameters of a tumor is presented. 
Here we can see that the tumor seems to be fairly symmetric out from the centre, but in both 
the k1 and k2 maps there is something interfering with this pattern.  
 
 
 
Figure 33: Area of high activity against area of less activity for an untreated CWR22 tumor.  
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Figure 34: Maps of the k-parameters in the xz-plane of tumors or the sagital/transverse plane. From 
left to right the index of the coronal value increases. This is a CWR22 tumor that received 7.5 Gy.  
 
4.1.5 Investigation of the input parameters of the model 
The non-linear regression model used demands initial estimates of the various parameters to 
be calculated. Several different initial “guesses” of the k-parameters into the model was used 
to investigate whether this affected the results. In Table 1 the results of changing the initial k1 
value (normally set to 0.3 min-1) is displayed.  
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  Test mouse 1   Test mouse 2   Test mouse 3 
k1 k2 k3 k1 k2 k3 k1 K2 k3 
K1=0 2,78E-06 0,5 0,1 2,68E-06 0,5 0,1 3,29E-06 0,5 0,1
K1=0,05 0,075014 0,249436 0,025316 0,081373 0,33766 0,040026 0,127239 0,558205 0,052117
k1=0,1 0,074996 0,249428 0,025371 0,081367 0,337625 0,040021 0,127359 0,559442 0,05206
k1=0,2 0,075186 0,250828 0,025431 0,081361 0,337633 0,040025 0,127354 0,55917 0,052116
k1 = 0,3 0,07509 0,250305 0,025428 0,081365 0,337555 0,040026 0,127356 0,559216 0,052099
K1=0,4 0,075054 0,250286 0,025427 0,081361 0,337646 0,04002 0,127359 0,559178 0,052095
K1=0,5 0,075204 0,250258 0,025427 0,08135 0,33764 0,040027 0,127356 0,559332 0,052084
K1=0,6 0,075097 0,250831 0,025431 0,081359 0,337656 0,040022 0,127348 0,559205 0,052073
K1=0,7 0,075054 0,250147 0,025431 0,081368 0,337663 0,040022 0,12737 0,559233 0,05209
K1=0,8 0,075099 0,250294 0,02543 0,081375 0,337691 0,040024 0,127365 0,559141 0,052106
K1=0,9 0,075094 0,250232 0,025428 0,081356 0,337674 0,040022 0,127369 0,559049 0,052101
K1=1 0,075041 0,250097 0,025429 0,081367 0,337742 0,040017 0,127342 0,559352 0,052099
K1=10 0,075003 0,249429 0,025433 0,081372 0,337561 0,040022 0,127379 0,559361 0,052093
Table 1: Results of changing the initial k1-value (in bold).  
There are only minor changes to be seen here except when k1 is set to zero. This 
testing was done extensively, still the additional data showed no different results. 
4.1.6 Adding a blood fraction parameter to the model 
We also wanted to se how the resulting tumor functions would look like if we assumed that a 
part of the voxel contained blood. First a randomly selected voxel from each tumor was 
scrutinized. One of the voxel had a relative large increase in r2 following the introduction of 
the blood fraction and was worth a closer look, see Figure 35. For most voxels there wasn’t a 
great difference, but for 6 out of 16 voxels the r2 was more or less increased. See Table 2. 
 
 
Figure 35: On the left; old uptake and free/bound functions for a MAS 98.06 tumor. On the right; the 
functions after introducing the blood fraction parameter.  
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For the specific voxel in Figure 35 there is a significant difference between the k1 and 
k2 parameters as well as the r2. The initial spike coming from the activity in blood vessels 
inside this voxel can be clearly seen. For the entire tumors however the r2 doesn’t change 
much, but there is still some variation in the mean values (see Table 3).  
 
Number 
  k1     k2     k3   rkv   
Old New % Old New % Old New % Old New % 
3v 0,208 0,205 98,56 0,438 0,435 99,32 0,014 0,014 100 0,95 0,95 100
3h 0,2 0,184 92 0,414 0,391 94,44 0,015 0,016 106,7 0,97 0,97 100
1h 0,079 0,078 98,73 0,159 0,157 98,74 0,013 0,013 100 0,96 0,96 100
1v 0,141 0,138 97,87 0,211 0,209 99,05 0,008 0,008 100 0,98 0,98 100
2h 0,198 0,172 86,87 0,266 0,24 90,23 0,009 0,009 100 0,96 0,97 101,04
2v 0,203 0,159 78,33 0,312 0,264 84,62 0,005 0,005 100 0,94 0,98 104,26
5h 0,176 0,156 88,64 0,31 0,283 91,29 0,015 0,015 100 0,94 0,94 100
5v 0,155 0,137 88,39 0,345 0,317 91,88 0,014 0,015 107,1 0,95 0,96 101,05
6h 0,209 0,209 100 0,467 0,467 100 0,016 0,016 100 0,98 0,98 100
6v 0,183 0,14 76,5 0,389 0,32 82,26 0,019 0,021 110,5 0,92 0,97 105,43
        
6v2 0,137 0,137 100 0,34 0,34 100 0,069 0,069 100 0,94 0,94 100
6h2 0,087 0,087 100 0,354 0,353 99,72 0,107 0,107 100 0,97 0,97 100
1v2 0,208 0,113 54,33 0,513 0,312 60,82 0,035 0,041 117,1 0,84 0,92 109,52
1h2 0,172 0,169 98,26 0,374 0,37 98,93 0,039 0,039 100 0,96 0,96 100
2v2 0,143 0,078 54,55 0,239 0,149 62,34 0,016 0,017 106,3 0,51 0,81 158,82
2h2 0,069 0,069 100 0,133 0,133 100 0,027 0,027 100 0,98 0,98 100
Table 2: Results of adding blood fraction when looking at individual voxels. The percentage is that of 
the new value compared to the old. The first set of rows is from MAS 98.12 tumors, and the second for 
MAS 98.06 tumors.  
 
Control 
Number 
  k1     k2     k3   rkv 
Old New % Old New % Old New % Median
5v_101209 0,076 0,073 96,053 0,507 0,588 116 0,039 0,068 174,36 0,97
5h_101209 0,05 0,05 100 0,234 0,29 123,9 0,035 0,066 188,57 0,98
1v2_130110 0,078 0,074 94,872 0,276 0,266 96,38 0,025 0,025 100 0,97
1h2_130110 0,075 0,074 98,667 0,25 0,247 98,8 0,025 0,025 100 0,97
4v_130110 0,081 0,076 93,827 0,337 0,315 93,47 0,04 0,039 97,5 0,99
4h_130110 0,076 0,071 93,421 0,286 0,264 92,31 0,029 0,029 100 0,99
7,5Gy 
Number 
  k1     k2     k3   rkv 
Old New % Old New % Old New % Median
11v_081209 0,125 0,124 99,2 1,163 1,161 99,83 0,047 0,048 102,13 0,91
15v_081209 0,021 0,021 100 1,533 1,437 93,74 0,662 0,69 104,23 0,94
15h_081209 0,095 0,095 100 1,015 1,013 99,8 0,308 0,329 106,82 0,97
5v2_130110 0,076 0,074 97,368 0,324 0,312 96,3 0,071 0,072 101,41 0,98
51v_130110 0,107 0,093 86,916 0,454 0,393 86,56 0,071 0,071 100 0,97
6v_130110 0,127 0,109 85,827 0,599 0,477 79,63 0,052 0,052 100 0,98
6h_130110 0,162 0,133 82,099 0,442 0,372 84,16 0,033 0,034 103,03 0,97
Table 3: Results of adding blood fraction when looking at whole tumor. The percentage is that of the 
new value compared to the old. These data are from the CWR22 tumors. 
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4.2 TAC 
4.2.1 TAC for treated tumors against controls  
The normalized time activity curve is a basic approach to investigate a tumor. As can be 
seen from Figure 36, there is clear distinction in normalized TAC between the treated and 
untreated CWR22 tumors. The irradiated tumors accumulate more FDG and have a greater 
internal variance than the control group. A graph displaying the p-values following T-testing 
for each time point is given in Figure 38 below. 
 
Figure 37: TAC for CWR22 xenografts with standard errors shown. 
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Figure 38: p-values for the CWR22 TAC curve (not real time on x axis) 
For most time points there is a statistical significant difference, but it is more 
pronounced at the end of the time series.  
4.2.2 TACs of the MAS 98.12 and MAS 98.06 tumors 
As can be seen in Figure 39, the MAS 98.12 line seems to have a more rapid uptake than 
the MAS 98.06 line. But as the MAS 98.06 line does not reach its maximum during the assay 
its final value is greater than that of the MAS 98.12 line. The p-value following T-testing is 
shown in Figure 40. Except for the time points where the curves cross each other, there is a 
significant difference between the two groups.  
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Figure 39: TAC for MAS 98.12 and MAS 98.06 tumor with standard errors shown 
 
 
Figure 40: p-values for MAS 98.12 and MAS 98.06 TAC (not real time on x-axis). 
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4.3 Pharmacokinetic parameters 
4.3.1 Median parameters of the CWR22 
By investigating the pharmacokinetic parameters calculated, more information about the 
tumors might be obtained. The median values of the k-parameters for the different groups of 
CWR22 xenografts are shown in Figure 41 below. There is borderline statistical significance 
for k1 and k2, but not for k3. 
 
Figure 41: Median k-parameters for each CWR22 tumor in the different groups. The statistical test 
gives the following p-values; for k1 the p-value 0.06, for k2 the p-value 0.04, for k3 the p-value 0.14. 
 
4.3.2 Median parameters of the MAS 98.12 and MAS 98.06 
In figure 42, median k1-k3 values are shown for of the MAS 98.12 and MAS 98.06 tumors. Comparing 
the two groups, the p-value for k1 and k2 indicates no significance, but k3 was highly different. 
   
Figure 42: Median k-parameters for each MAS 98.12 and MAS 98.06 tumor. For k1 the p-value is 
0.06, for k2 the p-value is 0.92 for k3 the p-value is << 0.01. 
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4.3.3 Histograms and percentile charts of CWR22 
In the following, investigations of the tumor heterogeneity will be presented. In Figure 43, the 
mean histogram of k1 values across all voxels in treated and untreated tumors is shown. 
Note that the histogram will not represent the distribution of any one tumor, but the 
distribution of the entire group of collected voxels.  
 
 
Figure 43: Histogram of k1 values for CWR22 xenografts. G0 is the control group and g1 is the one 
that got a dose of 7.5Gy. 
The two histograms in Figure 43 are clearly dififferent. It is therefore useful to look at 
the percentile values for these histograms and the p-values for each percentile. The median 
is the 50 percentile, where 50% of the data is below this value. The percentile value for all 
the 1-99 percentiles is calculated in the same way.  
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Figure 44: p-values for the percentiles of the k1 for CWR22 tumors. The solid line corresponds to a p-
value of 0.05. 
In Figure 44 it is shown that by looking at k1 values larger than the median significant 
difference between the groups can be found. The histograms in Figure 45 show that there is 
a difference in the k2 values as well. Figure 46 indicates significant differences around the 
median value of k2.  
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Figure 45: Histogram of k2 values for CWR22 xenografts. G0 is the control group and g1 is the one 
that got a dose of 7.5Gy. 
 
 
Figure 46: p-values for the percentiles of the k2 for CWR22 tumors. The solid line corresponds to a p-
value of 0.05. 
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Figure 47: Histogram of k3 values for CWR22 xenografts. G0 is the control group and g1 is the one 
that got a dose of 7.5Gy. 
The histograms for k3 are not as distinctive as before, and the p-values reveal that 
there is no way to distinguish the groups by looking at the k3 percentiles.  
 
 
 
Figure 48: p-values for the percentiles of the k3 for CWR22 tumors. The solid line corresponds to a p-
value of 0.05. 
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4.3.4 Histograms and percentile charts of MAS tumors. 
Histograms of MAS 98.12 and MAS 98.06 tumors were also compared using T-tests. For k1, 
Gaussian-looking histograms appear (Figure 49).. No statistical significance was found for 
the median values of k1, but according to the chart in Figure 50 it seems that there is 
significance for lover percentile values. 
 
 
 
 
Figure 49: Histogram of k1 values for the other xenografts. G0 is MAS 98.12 group and g1 is the MAS 
98.06 group. 
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Figure 50: p-values for the percentiles of the k1 for MAS 98.12 and MAS 98.06 tumors. The solid line 
corresponds to a p-value of 0.05. 
 
For k2, the distributions in Figure 51 are highly overlapping. Figure 52 show that no 
significant differences were found. 
 
 
 
Figure 51: Histogram of k2 values for the other xenografts. G0 is MAS 98.12 group and g1 is the MAS 
98.06 group. 
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Figure 52: p-values for the percentiles of the k2 for MAS 98.12 and MAS 98.06 tumors. The solid line 
corresponds to a p-value of 0.05. 
 
For k3, Figure 54 seems display the clearest distinction between the groups so far. The p-
value chart shows highly significant p-values (Figure 53). 
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Figure 54: Histogram of k3 values for the other xenografts. G0 is MAS 98.12group and g1 is the MAS 
98.06 group. 
 
 
Figure 55: p-values for the percentiles of the k3 for MAS 98.12 and MAS 98.06 tumors. The solid line 
corresponds to a p-value of 0.05. 
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4.4 The Patlak plot and calculation of MRglc 
 
Using Patlak analysis, the slope of the line shown in Figure 56 is linearly related to the 
observed value for metabolic rate of glucose. By doing this for each tumor, there is a new 
way of finding differences between the groups.  
 
 
Figure 56: A typical Patlak plot. The slope of the regressed line shown is proportional to the MRglc of 
the tumor.  
4.4.1 Patlak and MRglc for CWR22 tumors.  
In Figure 57 the results of both methods for calculating the MRglc (via pharmacokinetic and 
Patlak analysis, respectively) is shown. For the first data set this evaluation yield a p-value 
<< 0.01 for both the Patlak and pharmacokinetic analysis, respectively. However, it can be 
seen from the plots in Figure 57 that the MRglc estimate for the treated group by using k-
parameters show a wider spread. 
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Figure 57: MRglc estimate on the CWR22 data, from Patlak plot on the left and from k-parameters on 
the right. 
4.4.2 Patlak and MRglc for MAS 98.12 and MAS 98.06 
For the MAS 98.12 and MAS 98.06 data, the two methods of analysis both gives highly signicant 
results (Figure 58). 
  
Figure 59: MRglc estimate on the MAS 98.12 and MAS 98.06 data, from Patlak plot on the left and 
from k-parameters on the right.  
  
4.5 Other investigations 
In the end of this chapter other and maybe more unusual surveys have been conducted. 
4.5.1 Blood fraction of the tumors 
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It was previously investigated if adding the blood fraction parameter would improve the 
model. This later led to testing if the blood fraction would be different between groups of 
tumors (see Figure 60). There doesn’t seem to be huge differences between the groups 
unless one counts the larger spread of the irradiated tumors. The Student’s t-test did not 
show statistic significance between the groups.  
 
 
 
Figure 60: The median blood fraction for the different tumors.  
 
4.5.2 Time dependant k-parameter histograms 
To investigate the way FDG distribution in the tumor varies over time, several histograms 
have been created. See Figure 61 and Figure 62. 
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Figure 61: Histograms of voxel activity as a function of time for one tumor. Not that the y-axis is limited 
to 30.  
These histograms is just for some of the time points, a full 2D histogram of all time 
points is shown as well in Figure 62. 
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Figure 62: 2D histogram of voxel activity as a function of time for one tumor. The color scale 
represents height of the bins, red is high.  
4.5.3 Dependence on distance from centre of tumor 
In this part, the dependence on distance from centre of tumor for the various parameters was 
investigated . A linear relationship between the metabolic rate of glucose and distance from 
center of tumor is apparent, and Figure 63 shows this for one tumor. No large differences in 
the radial dependence could be found, although the data may indicate a higher metabolic 
rate in the center of tumor and that some tumors have a greater dependency of the distance 
from the center of the tumor than others.  
 
 
    correlation to distance from center of tumor   
k1g0 -0,0638 k2g0 0,258 k3g0 -0,219 MRg0 -0,585 
k1g1 0,258 k2g1 0,309 k3g1 -0,229 MrRg1 -0,414 
p-value 0,569 p-value 0,978 p-value 0,973 p-value 0,27 
Table 4: k value and MR dependency on distance from center of tumor for CWR22. G0 is control 
group and g1 got a dose of 7.5 Gy. 
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    correlation to distance from center of tumor   
k1g0 -0,0732 k2g0 0,0577 k3g0 -0,273 MRg0 -0,678 
k1g1 0,086 k2g1 0,226 k3g1 -0,405 MRg1 -0,756 
p-value 0,167 p-value 0,501 p-value 0,456 p-value 0,578 
Table 5: k value and MR dependency on distance from center of tumor for breast cancer. G0 is MAS 
98.12 and g1 is MAS 98.06. 
 
 
Figure 63: Top left; k1 versus distance from center of tumor, correlation 0,11. Top right; k2 versus 
distance, correlation 0,37. Bottom left k3 versus distance, correlation -0,63. Bottom right; Metabolic 
rate of glucose versus distance, correlation -0.901. 
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5 Discussion 
5.1 General issues of diagnostic imaging 
In the field of imaging there are several restrictions and sources of error. Let’s start with the 
ultimate challenge; to choose between noise, resolution, dose and acquisition time. In most 
imaging modalities, especially for CT, you usually can’t change one variable for the better 
unless another variable is changed for the worse. For example better resolution indicates 
smaller voxels, which will reduce the signal to noise ratio (SNR). To keep the SNR constant 
the tube current can then be increased. However, there are no side effects from building a 
better detector, and the problem is not impossible.  
These issues exist for PET as well, but there are some differences that make the 
choices easier. For a dynamic PET scan it is more or less the biology of the system that is 
investigated that decides the acquisition time needed. The time resolution can be variable 
across the time series. A good time resolution is chosen where the activity measured is 
assumed to change rapidly. For this study the highest  time resolution used was 10 seconds. 
As already mentioned, better resolution (in any of the four dimensions) will reduce the SNR.  
The SNR is a coefficient that tells us how much of the displayed changes are due to 
noise and how much is due to actual differences in the underlying biology. If we are looking 
at very small changes in tissue a high SNR is needed. By increasing the voxel size a better 
SNR can be obtained. But the problem with large voxels is the partial volume effect; the 
same voxel can contain various types of tissue and only the mean across the voxel will be 
shown. 
 For this specific study we try to investigate the heterogeneity of the tumor and would 
therefore like to reduce the voxel size as much as possible. In PET the voxel size is 
restricted by the machinery itself and in general new machines improve the resolution. The 
small PET scanner used in this study for example got much better resolution than a normal 
scanner used in the clinics. An other problem with PET is that only in the center of the 
scanner is the data correctly recorded, I think they get skewed or something away from the 
center. (I will check up on this / explain properly later).  
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5.2 Specific issues for this study 
5.2.1 Tumor delineation 
The tumor delineation has been done by an untrained hand and not properly looked over by 
a radiologist. The delineation was done as similar as possible on all tumors. The goal was to 
trace the edges of the tumors but has most likely resulted in both clipping away pieces of the 
tumor and including some outlying tissue. 
5.2.2 The arterial input function 
The model used for pharmacokinetics and the time activity curve both depend on the arterial 
input function. The arterial input function is a measure of the FDG availability in blood plasma 
close to the cells. The general assumption is that each voxel lie next to a blood vessel and 
interchange FDG with this blood vessel only.  
In this study small mammals (mice) are the subject of the PET assay and their 
arteries is too small to identify in PET images. The artery function could technically have 
been found by measuring blood samples from the mice. But taking blood samples from three 
mice every 10 seconds is not possible, and a total of 37 samples (same number of time 
points used in one assay) would probably drain the mouse dry. Therefore a procedure for 
determining the “arterial” input function by looking at the heart was derived. The resulting 
function was found viable for use as an arterial input function. We had to assume that the 
measured activity of the heart would mainly resemble the activity in the outlying blood 
vessels. A new model with an added time delay of the input function (assuming a transition 
time from heart to outlying blood vessels) showed no improvement of the model. This 
parameter was therefore removed from the final model used.  
There is another problem with measuring FDG activity in the blood as compared to 
other tracers. As FDG resembles and can be used by cells as normal glucose, the blood 
cells themselves can absorb some of the FDG. The activity measured in the heart will 
therefore include FDG trapped inside blood cells. Therefore not all the FDG assumed to be 
present are actually available for the tumor cells. (5). A way to measure the ratio between 
FDG inside blood cells and free in plasma has not been found. But as this is a problem that 
is similar for all mice involved the effect should be minimal.  
The final problem as so far found about the heart function is that the initial spike when 
the bolus pass the heart is quicker than we can correctly measure. As a result the peak is 
somewhat smeared out. Again, this affects all mice in a similar fashion.  
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5.2.3 The CWR22 dataset 
There were some problems concerning this dataset. The tumor delineation was not always 
easy. Worse, for two of the mice (11 and 15 in same image) finding an arterial input function 
was very difficult and a compromise had to be made. The data was recorded partly in 
december 2009 and partly in January 2010. This may have caused some variation in the 
reconstruction and scaling used. But as som mice from each group was imaged each time, 
this should not cause an effect that separate the groups.  
5.2.4 The MAS 98.12 and MAS 98.06 dataset 
As opposed to the other dataset, the delineation of tumors and extraction of the arterial input 
function was not a problem. Nevertheless, there were other problems. 
The first problem is that three different time resolutions were used. To solve this 
problem some steps had to be taken. In the part of the IDL program where the TACs were 
compared the time array for the first image that went through the routine was saved. All other 
time arrays and TAC data were then changed to fit the first time array by interpolation.  
The second problem with this dataset is that in most of the images we now had three 
mice at a time inside the scanner. This led to a larger time difference in between the mice as 
to when the FDG was administrated. To work around this problem, the time at which the 
heart function reached its peak was recorded for each tumor. All the TAC data recorded 
before this point was rejected and the time array was updated to fit this change. Then the 
data was subject to the same steps taken above in order to fit it into the time array used by 
other mice. This had to be done in order to produce correct pharmacokinetic parameters as 
well.  
Finally one mouse received a bad injection of FDG and the data acquired had to be 
discarded for this study.  
The steps taken should hopefully be enough to eliminate most of the effects these 
unwanted differences could cause. 
5.3 Investigations of the CWR22 data 
For this test we were trying to determine signs of early tumor response using FDG PET. 
Several different tactics were employed to deal with this problem. The first thing looked at 
was the uptake function itself, the normalized time activity curve (TAC).  
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5.3.1 The time activity curve 
From the graph presented (see Figure 37 on page 44) a stronger and stronger 
difference between the curves as time goes on was observed. The graph indicates that the 
irradiated tumors accumulate more FDG. At first this increased activity in treated tumors 
seems contra intuitive as we are expecting the tumor cells to die. Many different effect can 
cause variations of FDG uptake, among them is blood flow, oxygen availability and GLUT 
transporters. However there might be an other explanation; a common phenomenon referred 
to as “metabolic flare”. This is described as an increased metabolic rate or increased 
standard uptake value (SUV) of FDG following various treatments like radiotherapy, 
hormonal therapy and somewhat in chemotherapy. An article written by Basu Sandip and 
Nair Naendra has this to say about the matter; “The increase in FDG uptake accompanying 
radiotherapy during the initial 2–3 weeks following therapy is prominent in epithelial surfaces 
and is related to inflammatory infiltrate of neutrophils, lymphocytes, and macrophages.” “In 
general, at least an interval of 4 weeks (preferably 6–8 weeks) following radiotherapy is 
suggested to circumvent the misinterpretation. The minimum interval for re-evaluation after 
starting therapy, according to RECIST, is 4 weeks, where again, FDG PET can be 
comfortably applied.” (30) It appears like the suggestion is that we should have waited quite 
a lot longer before doing a PET assay on the mice. But we are actually trying to use FDG-
PET to find early response qualities. Others have also done these kinds of studies. The 
following article is not about RT but for hormonal therapy. In the article by F Dehdashti et. al. 
they have investigated whether this “metabolic flare” is a sign of a hormonally responsive 
breast cancer.  “There were seven responders and four nonresponders based on clinical 
follow-up. None of the responders had a clinical flare reaction, but all demonstrated 
metabolic flare, with a mean +/- standard deviation increase in tumor standardized uptake 
value (SUV) for FDG of 1.4+/-0. 7. No evidence for flare was noted in the nonresponders 
(change in SUV for FDG -0.1+/-0.4; P = 0.008 vs. responders).”” The findings of a metabolic 
flare by FDG-PET and the degree of ER blockade by FES-PET early after institution of 
tamoxifen treatment appear to predict responsiveness to antiestrogen therapy in patients 
with ER+ metastatic breast cancer” (31). Considering the findings in that study it still seems 
viable to do PET studies shortly after radiotherapy. Okay, back to the results. 
The p-value chart given off the TAC gives a slightly different picture than the TAC 
itself. It suggests a significant difference at the very beginning of the uptake. But after some 
consideration this result has been neglected. It would be dependant on how fast the FDG 
was administrated and the time resolution might not be good enough to capture the true 
curve. After 20minuntes there is already a statistical significance (p-value slightly below 0.05) 
but if we wait 10 more minutes it is reduced to about 0.01. So for this very specific assay, 
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monitoring the mouse for maybe 5 minutes, 30 minutes after administration of FDG, will be 
enough to determine the response.  
There was a group of mice that got 15 Gy but that was only 4 tumors in a total of 3 
mice, and the data are very variable. They go all across the chart and may suggest a change 
from the control values in either direction. Therefore these results have not been further 
discussed.  
One of the tumors (11v) receiving a dose of 7.5 Gy had TAC end values similar to the 
control group. There is several ways to interpret this. First, something might have gone 
wrong. For example that the tumor somehow was outside the field or the tumor delineation 
was faulty. The second and more optimistic explanation is that we might have singled out a 
radio resistant tumor. It could also just be a case of statistic fluctuations of the data. For the 
moment the answer to this question goes unanswered.  
5.3.2 Pharmacokinetic model 
By looking at the pharmacokinetic modeling more information about the tumors might be 
obtained. On a first glance increased values for all the estimated k-parameters can be seen 
for treated tumors. By looking at the whole tumor, statistic significance is reached for the k2 
parameter only. Next thing on the schedule is the k histograms. We can here easily see that 
the distribution of treated tumor voxels differ from that of untreated tumors. A recently applied 
test also gives the impression that the heterogeneity of the tumor itself might increase for 
treated tumors, although statistical significance was not reached. The closest was p-value of 
0.1 for k2. The table for this test will be added in the results or appendix. Another way to look 
at the k-parameters of the tumors is the percentile chart. Here we can find in what part of the 
tumor histogram that the differences between the groups is greatest. Again the data suggest 
stronger values for treated tumors and there is an area of the histograms for both k1 and k2 
that has statistical significance. There is still no statistic significance to be found for the k3 
parameter though. Still, the method of looking at each percentile of the tumor seems more 
robust than taking an average over the entire tumor. On a final note, the tumor mentioned 
above (11v) is shown as a treated tumor by looking at the k1 and k2 parameters, as it should 
be. However, now another treated tumor (5v2) got k1 and k2 values similar to the control 
group.  
5.3.3 Looking at the metabolic rate of glucose 
We can also look at the metabolic rate of the tumors using two different techniques. From 
using the Patlak plots an increased metabolic activity in the treated tumors with very good p 
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value is shown. The k-parameters found can also be combined to produce the same variable 
found in the Patlak plots. Even though these two methods should return the same variable, 
differences occur. These differences have been calculated to about 0-25%. It should then be 
mentioned that the Patlak plots give better results than the combined k-parameters. Again all 
the signs tell of more metabolic active tumors after treatment. Interestingly enough, the 5v2 
tumor look like a control tumor if we only look at the individual k parameters, but if we 
combine the parameters to obtain metabolic rate of glucose it shines through as a treated 
tumor. The 11v tumor however got a MRglc similar to the control group. It should be 
mentioned that the k3 parameter tips the scales in this calculation.  
5.3.4 TAC versus pharmacokinetics 
Now that the results from TACs and pharmacokinetics has been discusses, it is time to 
choose which method to use. The p-values obtained from the TAC are better than the p-
values from the pharmacokinetic modeling. The internal group variations are also larger for 
the various k parameters than that of the TAC values, if we consider the last time points of 
the TAC. From these observations, the TAC or even a single measurement of tumor activity 
gives stronger results than the pharmacokinetic modeling.  
The tumors in the control group are defined as controls in all the different tests done 
on them. In other words, none of the untreated tumors show signs of treatment response. 
Most of the treated tumors show response, but not all. The different tests might place the 
same tumor in different categories. Because of this, a full analysis including all the tests 
mentioned above might be useful to determine the true response of the tumor.  
5.4 Investigations of the MAS 98 xx data 
5.4.1 The time activity curve 
As can be seen from the TACs themselves and the following p-value chart, there is 
differences between the groups here. Here complete different shapes of the TAC curves can 
be seen as well. The curve from the MAS 98.12 data shows rapid uptake and then fading 
while the MAS 98.06 got slower uptake and doesn’t reach maximum intensity during the 
assay. This means that we can for example again use a one frame shot at about 40 minutes 
after administration of FDG (for mice) to see the difference between the groups. However 
there might be trouble getting an exact quantification of what the TAC at this point should be 
for a given group. Then one can turn to the entire series and see the actual shape of the 
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curve. By doing so it will be possible to discern a MAS 98.12 tumor from a MAS 98.06 by 
investigating the shape of the curve even if it is not proper normalized. For this reason, a full 
dynamic PET scan will be useful. A dynamic PET scan will also make it possible to obtain 
more useful data, like the k parameters from pharmacokinetic modeling. 
5.4.2 Pharmacokinetic modeling 
From the results it is apparent that the MAS 98.12 line got higher values of k1 than that of 
MAS 98.06 and that there is significant difference between the groups. For the k2 parameter 
however, the data are much too similar. The k3 parameter got the best statistical 
significance, where the values for MAS 98.06 are greater than that of MAS 98.12. For this 
dataset the k-parameters also seem to be a good measure on what group the selected tumor 
belongs in. Again it can be useful to have a look at the distribution of the k-parameters. In the 
first histogram it seems that the k1 values for both groups follow a similar skewed Gaussian 
distribution with the one for MAS 98.12 is shifted to higher values. The p-value chart for each 
percentile in the tumors show good statistical difference for most of the tumor, proving that k1 
is a good parameter to distinguish these groups. As expected the k2 histogram and p-value 
chart does not show a big difference between the groups. The shape of the histograms is 
different, but that might just be because of the way they are created. Again we see good 
differences when looking at the k3 values. The p-value across percentiles is exceptionally 
good, and the histograms shows two completely different distributions. This shows that the k 
parameters both by looking at the entire tumor and by looking at the percentiles may very 
well be used to characterize tumors along with the TAC. 
5.4.3 Metabolic rate of glucose 
The calculated MRglc using both Patlak plots and combination of the k parameters yield a 
good p-value and the result that the MAS 98.06 line is more metabolic active than the MAS 
98.12. The developers of these lines found similar results (23). Again the more simple 
method applied in the Patlak plot trumps the more difficult pharmacokinetic model. 
5.4.4 TAC versus pharmacokinetics 
For this dataset both the TACs and the k-parameters could alone distinguish the different 
tumors. That is not so surprising, as this dataset was a lot more homogenous than the 
previous. It does seem however that it would be enough with one or more measurements of 
the tumor activity to correctly classify the tumor. Then again, this is for the when assuming 
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that we already know that it is either MAS 98.12 or MAS 98.06 that we are looking at. If in the 
future there will be more tumor types and characteristics to choose between, a full 
exploration of the pharmacokinetic variables might prove useful as well.  
5.5 Radial dependency 
In this study it has been investigated if there is a relationship between the parameter values 
and the distance from the centre of the tumor. For the various k parameters there have been 
no clear signs of such a relationship. The charts in Figure 63 for k1 and k2 increase at the 
end of the tumors. This is most likely because these voxels have better blood availability and 
therefore higher rate constants for FDG exchange with blood plasma. For the metabolic rate 
of glucose however, there is a slight indication that the MRglc is higher in the middle of the 
tumor. This is quite contra-intuitive if we look at two aspects of tumor biology. The blood 
network inside a tumor is usually not structured as it is in normal tissue (2). Tumor cells far 
from blood vessels should therefore receive less oxygen, and many large tumors have 
necrotic areas in the middle. From the data collected however it doesn’t seem to be much 
signs of necrosis in the midst of the tumor. So all right, there is activity and live tumor cells in 
the middle of the tumor. Still they should receive less blood, therefore less oxygen and 
therefore have less to work with in order to metabolize glucose.  
The other thing most cells need to grow is growth factors. The xenografts in the first 
data set are androgen dependant, and should therefore behave in a way that shows the 
tumor cells close to blood vessels grow and metabolize faster than the rest. It is therefore 
established that a tumor normally grows from the rims and out. There is no sign of this in any 
of the data collected. There can however be some imaging reasons for this. First we must 
consider the partial volume effect. If this outer layer of fast growing tumor cells are thinner 
than the width of the voxels (0,87mm) there is a good chance that some of the voxel will 
contain cells that are outside the tumor, and thus lower the activity level of the entire voxel. 
The other reason that might cause higher activity in the center of tumors is the reconstruction 
algorithms. In particular the filters that have to be used to subdue “false data”. These filters 
might be prone to favor centers of activity more than the edges. A good filter should be able 
to correctly display a homogenous cylinder, but this might not always be the case. In the 
article by (32) they have done some investigations on this subject using phantoms. They 
were mainly interested in small tumors and resulting partial volume effect, but from the 
picture presented in the article even the 12mm “tumor” showed higher activity in the middle 
of the tumor. Their results also showed that the signal obtained is dependant on the 
smoothing filters used. Both these effects can explain why the tumor looks more active in the 
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center than at the edges. As we have not been able to confirm the data with histology one 
can only speculate in what is the true answer. If these mechanisms have a significant effect 
in perturbing the data, one must make sure works that shall be compared use the same 
algorithms.  
As we can still see significant difference between groups in the dataset presented, we 
might assume that doing the same error for all data is more or less ok when comparing the 
data in a qualitative study. Either way, there were little differences to be found in between the 
groups in this aspect. Both groups have more or less the same radial dependence for MRglc. 
It can be noted that the relationship is stronger for the MAS 98 xx tumors than the CWR22 
tumors.  
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5.6 Conclusions 
After completing various tests it seems like the simple TACs and the Patlak plots are the best 
parameters in order to characterize tumors and response. 
When looking at the k-parameters of the CWR22 tumors, the median values are not 
always the best to distinguish the groups. It should therefore be considered investigating all 
the percentiles. It follows that choosing a random subset of voxels (or cells like in biopsy) 
might not be sufficient in order to characterize the tumor.  
5.7 Further work 
As mentioned for the CWR22 data, some tests show treatment response in some tumors and 
not in other tumors. It would have been interesting to investigate the response of these select 
tumors in other ways, say by histology or measure size over a long period of time. This 
should be done in order to know what actually happened to these tumors, are they 
responders or not.  
Monitoring the same tumor before treatment and after treatment as was originally 
intended for this project might also provide valuable results.  
If the method for determining differences between tumors lines is desired for the 
clinic, a lot of work is ahead. Then characterization data of many more tumors must be 
recorded, and by doing so maybe more common traits of aggressive tumors can be found.  
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A.2 Checklist for animal experiments 
Animal: 
Arrival date:  -  
Species: Nude mice 
Strain: BALB/c  
Supplier: Bred at the Radium hospital 
Number: 10/13 
Age and weight at start of experiment: 30-35 g, 6-8 weeks old 
Sex: Male/ 
Quality category: SPF 
Fasted before experiment: 10hours before PET imaging 
Environment: 
Type: barrier 
Temperature: 21 +/- 1 Co  
Daylight in the animal room: No 
Light/Dark cycle: 12 hours light cycle starting at 07:00, giving 200lux in the middle of the 
room and about 100lux in the cages. 
Relative humidity: 60 +/- 5% 
Air recycling: - 
Cages/Housing: 
Cage location: Cages were kept inside a cabinet 
Cage type and size: Type III 
Number of animals in each cage: 8-10 
Environmental enrichment: paper and cardboard houses 
Cage changes per week: 2 times a week 
Feed: 
Producer: Special diet services, UK 
Consistence: Pellets 
Availability: ad libitum 
Litter/bedding: 
Product name: Scanbur BK 
Type: Shavings 
Sterility: Heated 
Consistency: chips 
Water: 
Type: Tap water  
Sterility: some added HCL 
Availability: ad libitum 
Health assessment: 
A list of information at the lab for each individual animal 
Euthanasia: 
Date: At end of experiment 
Method: Swift dislocation of the neck 
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A.2 Codes in Interactive Data Language 
 
Main program for obtaining tumor data.  
DEVICE, DECOMPOSED = 0 
common art, arter 
!EXCEPT=0 
print, 'Choose folder for data extraction' 
fileloc='' 
read, fileloc, prompt="Enter extraction location" 
cd, fileloc 
files = FILE_SEARCH('*', COUNT=n_images) 
obj = OBJ_NEW('IDLffDICOM') 
read = obj->Read(files(0)) 
date_dic = obj->GetValue('0008'x, '0020'x) 
date_dic = *date_dic[0] 
dim_xy = obj->GetValue('0028'x, '0010'x) 
dim_xy = *dim_xy[0] 
dim_z = obj->GetValue('0054'x, '0081'x) 
dim_z = *dim_z[0] 
dim_time = obj->GetValue('0054'x, '0101'x) 
dim_time = *dim_time[0] 
res_z= obj->GetValue('0018'x, '0050'x) 
res_z = float(strcompress(strmid(*res_z[0], 0,6), /REMOVE_ALL)) 
res_xy= obj->GetValue('0028'x, '0030'x) 
res_xy = float(strcompress(strmid(*res_xy[0], 0,6), /REMOVE_ALL)) 
inst=intarr(n_images) 
for i=0, n_images-1 do begin 
 read = obj->Read(files(i)) 
 dum = obj->GetValue('0054'x, '1330'x) 
 inst(i) = *dum[0] 
 ptr_free, dum 
endfor 
sort_ind=sort(inst) 
bilder=dblarr(dim_xy, dim_xy, dim_z, dim_time) 
time=fltarr(dim_time) 
z_ind=0 
time_ind=0 
for i=0, n_images-1 do begin 
 ind=sort_ind(i) 
    read = obj->Read(files(ind)) 
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  dum = obj->GetValue('7fe0'x, '0010'x) 
    bilder(*,*, z_ind, time_ind)=double(rotate(*dum[0], 7)) 
;Scaling korreksjon 
    resc = obj->GetValue('0028'x, '1053'x) 
    ;resca=double(strcompress(strmid(*resc[0], 0, 10), /REMOVE_ALL)) 
    resca=double(*resc[0]) 
    bilder(*,*, z_ind, time_ind)=bilder(*,*, z_ind, time_ind)*resca 
    z_ind=z_ind+1 
    if z_ind eq dim_z then begin 
       tim = obj->GetValue('0018'x, '1242'x) 
       time(time_ind)=*tim[0] 
       time_ind=time_ind+1 
       z_ind=0 
    ptr_free, tim 
    endif 
    ptr_free, dum, resc 
endfor 
OBJ_DESTROY, obj 
;These lines make a new time array, where the new time is the time called "image time" in the tag plus 
;half the "actual frame duration" 
timeElapsed=0 
for i=0, dim_time-1 do begin 
 timeDummy=time(i) 
 time(i)=timeElapsed+(1/2.0)*time(i) 
 timeElapsed=timeElapsed+timeDummy 
endfor 
time(0)=0 
time=time/1000 
print, tim 
time=time/60. 
 
;Because of memory problems, we'll try to cut up the picture a bit 
window, 0, xsize=dim_xy*4, ysize=dim_xy*4, TITLE = 'click bottom left corner of new image(make it 
quadratic)' 
tvscl, rebin(bilder(*,*,60,round(dim_time/2.0)), 4*dim_xy, 4*dim_xy, 1, 1, /SAMPLE) 
cursor, xpo, ypo, 4, /DEVICE 
xpo=round(xpo/4.0) 
ypo=round(ypo/4.0) 
startx=xpo 
starty=ypo 
window, 0, xsize=dim_xy*4, ysize=dim_xy*4, TITLE = 'click upper right corner of new image' 
tvscl, rebin(bilder(*,*,60,round(dim_time/2.0)), 4*dim_xy, 4*dim_xy, 1, 1, /SAMPLE) 
cursor, xpo, ypo, 4, /DEVICE 
xpo=round(xpo/4.0) 
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ypo=round(ypo/4.0) 
endx=xpo 
endy=ypo 
newdimx=endx-startx 
newdimy=endy-starty 
if newdimx gt newdimy then begin 
 dim_xy=newdimx 
endif else begin 
 dim_xy=newdimy 
endelse 
alreadycutted =0 
print, 'Did you alredy do that for this mouse?' 
read, alreadycutted, prompt="Type 1 for yes, or 0 for no" 
if alreadycutted then begin 
 print, 'Then gimmi the folder name!!!!!!!!' 
 fileloc101='' 
 read, fileloc101, prompt="I am waiting..." 
 cd, fileloc101 
 restore, filename='bildecutting.sav' 
 startx=bildecutting(0) 
 starty=bildecutting(1) 
 dim_xy=bildecutting(2) 
endif else begin 
 bildecutting=[startx,starty,dim_xy] 
endelse 
xcounter=startx 
ycounter=starty 
newbilder=dblarr(dim_xy,dim_xy,dim_z,dim_time) 
for timemake = 0, dim_time-1 do begin 
 for zmake = 0, dim_z-1 do begin 
  for xmakeover = 0, dim_xy-1 do begin 
   for ymakeover = 0, dim_xy-1 do begin 
   
 newbilder(xmakeover,ymakeover,zmake,timemake)=bilder(xcounter,ycounter,zmake,timemake) 
    ycounter=ycounter+1 
   endfor 
   ycounter=starty 
   xcounter=xcounter+1 
  endfor 
  xcounter=startx 
 endfor 
endfor 
bilder=0 
bilder=newbilder 
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newbilder=0 
;These 3 lines call upon functions that will find the intensity function of the heart and the turmour region. 
arterieF=findheartfunction(dim_xy,dim_z,time,bilder) 
bildesett=bilder(*,*,*,dim_time-1) 
TumourR=findtumorregion(bildesett) 
;TumourR=findtumorregionboost(bildesett) 
stop 
save, filename='bildecutting.sav', bildecutting 
save, filename='arterieF.sav', arterieF 
save, filename='tumorRegion.sav', TumourR 
;restore, filename='tumorRegion.sav' 
;This is an adittional set of data made in the previous funtion that is needed later. 
restore, filename='kartkoord.sav' 
loadct, 0 
;The follwing is the steps to calculate the tumour functions free, bound and the k-values 
index=where(TumourR) 
parinfo = replicate({value:0.0D, fixed:0, limited:[0,0], limits:[0.D,0], relstep: 0.0D, tied:''}, 5) 
;parinfo = replicate({value:0.0D, fixed:0, limited:[0,0], limits:[0.D,0], relstep: 0.0D, tied:''}, 4) ;Change this 
when... 
parinfo[0:2].limited[0] = 1 
parinfo[0:2].limits[0]  = 0.D 
parinfo[0:2].relstep = double(1.0e-4) 
parinfo[3].fixed=1 
parinfo[4].limited[0] = 1 ;Change this when switching artery parameter on/off 
parinfo[4].limits[0]  = 0.D ;Change this when switching artery parameter on/off 
 
 
k1_in=0.3 
k2_in=0.5 
k3_in=0.1 
k4_in=0.0 
vb_in=0.05 ;Change this when switching artery parameter on/off 
func=fltarr(dim_time) 
func_err=fltarr(dim_time) 
stat=intarr(dim_xy,dim_xy, dim_z) 
rkv=fltarr(dim_xy,dim_xy, dim_z) 
k1=fltarr(dim_xy,dim_xy, dim_z) 
k2=fltarr(dim_xy,dim_xy, dim_z) 
k3=fltarr(dim_xy,dim_xy, dim_z) 
k4=fltarr(dim_xy,dim_xy, dim_z) 
CF=fltarr(dim_xy,dim_xy, dim_z, dim_time) 
CB=fltarr(dim_xy,dim_xy, dim_z, dim_time) 
bilder_fit=fltarr(dim_xy,dim_xy, dim_z, dim_time) 
fak=8 
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time_interpol=dindgen(fak*dim_time)*(max(time)-min(time))/(fak*dim_time-1) 
arter=interpol(arterieF, time, time_interpol) 
func_err_inter=time_interpol*0+0.001 
func_err=dblarr(dim_time) 
par=double([k1_in, k2_in, k3_in, k4_in, vb_in]);, t0]) Change this when switching artery parameter on/off 
;par=double([k1_in, k2_in, k3_in, k4_in]);, t0]) 
i1=long(0) 
i=long(0) 
fi=1 
while i lt n_elements(index) do begin 
 ind=array_indices(stat, index(i)) 
 start_z=ind(2)-fi 
 if start_z lt 0 then begin 
  start_z=0 
  dum=fltarr(2*fi+1,2*fi+1,fi+1, dim_time) 
 endif else begin 
  dum=fltarr(2*fi+1,2*fi+1,2*fi+1, dim_time) 
 endelse 
 dum(*,*,*,*)=bilder(ind(0)-fi:ind(0)+fi, ind(1)-fi:ind(1)+fi,start_z:ind(2)+fi,*) 
 for j=0, dim_time-1 do begin 
  func(j)=mean(double(dum(*,*,*,j))) 
  func_err(j)=stdev(double(dum(*,*,*,j))) 
 endfor 
    func_inter=double(interpol(func, time, time_interpol)) 
    func_err_inter=0*double(interpol(func_err, time, time_interpol))+1.0 
    res=MPFITFUN('trekomp', time_interpol, func_inter, func_err_inter, par, PARINFO=parinfo, 
YFIT=func_fit, STATUS=status, QUIET=1, MAXITER=200, FTOL=1e-3, /DOUBLE) 
    bilder_fit(ind(0), ind(1),ind(2),*)=interpol(func_fit, time_interpol, time) 
    k1(index(i))=res(0) 
    k2(index(i))=res(1) 
    k3(index(i))=res(2) 
    k4(index(i))=res(3) 
    stat(index(i))=status 
    rkv(index(i))=correlate(interpol(func_fit, time_interpol, time), func)^2.0 
 CF(ind(0), ind(1),ind(2),*)=interpol(free(time_interpol, res), time_interpol, time) 
 CB(ind(0), ind(1),ind(2),*)=interpol(bound(time_interpol, res), time_interpol, time) 
 func_avg=fltarr(dim_time) 
 func_fit_avg=fltarr(dim_time*8) 
 func_free_avg=fltarr(dim_time*8) 
 func_bound_avg=fltarr(dim_time*8) 
    i=i+1 
endwhile 
save, filename='k1.sav', k1 
save, filename='k2.sav', k2 
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save, filename='k3.sav', k3 
save, filename='rkv.sav', rkv 
save, filename='status.sav', stat 
;This next part will choose voxels containing tumour functions with rkv greater than 0.5, 
;and print out the median function and k-values for the entire tumour 
index=where(TumourR gt 0 and rkv gt 0.5) 
func_avg=fltarr(dim_time) 
func_fit_avg=fltarr(dim_time) 
func_free_avg=fltarr(dim_time) 
func_bound_avg=fltarr(dim_time) 
dum=fltarr(dim_xy, dim_xy, dim_z) 
for i=0, dim_time-1 do begin 
 dum(*,*,*)=bilder(*,*,*,i) 
 func_avg(i)=median(dum(index)) 
 dum(*,*,*)=bilder_fit(*,*,*,i) 
 func_fit_avg(i)=median(dum(index)) 
 dum(*,*,*)=CF(*,*,*,i) 
 func_free_avg(i)=median(dum(index)) 
 dum(*,*,*)=CB(*,*,*,i) 
 func_bound_avg(i)=median(dum(index)) 
endfor 
res(0)=median(k1(where(k1 gt 0))) 
res(1)=median(k2(where(k2 gt 0))) 
res(2)=median(k3(where(k3 gt 0))) 
rkvmean=median(rkv(where(rkv gt 0))) 
loadct, 0 
window, 0, xsize=768, ysize=700 
plot, time,func_avg, psym=4,  BACKGROUND=255, COLOR=0, CHARSIZE=2, YTITLE='Relative 
Activity', XTITLE='Time (min)' 
oplot, time,func_fit_avg, COLOR=0, THICK=2 
oplot, time,func_free_avg, COLOR=0, linestyle=1, THICK=2 
oplot, time,func_bound_avg, COLOR=150, linestyle=2, THICK=2 
xyouts, 220,610, 'k1',  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 320,610, 'k2',  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 420,610, 'k3',  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 520,610, 'k4',  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 620,610, 'r2',  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 190,580, strmid(strcompress(string(res(0))), 0, 6),  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 290,580, strmid(strcompress(string(res(1))), 0, 6),  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 390,580, strmid(strcompress(string(res(2))), 0, 6),  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 490,580, strmid(strcompress(string(res(3))), 0, 6),  CHARSIZE=2, COLOR=0, /DEVICE 
xyouts, 590,580, strmid(strcompress(string(rkvmean)), 0, 5),  CHARSIZE=2, COLOR=0, /DEVICE 
TumorF_jpg=TVREAD(Filename = 'TumourF', /JPEG, QUALITY = 100) 
;window, 3, xsize=4*dim_xy, ysize=4*dim_z 
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;The following 9 lines creates the k-value maps 
;As you can see below, the size of the picture arrays decrease for each new k-parameter. This is in order 
to show 
;them all in the same picture, without the ones applied later writes over the image of the ones printed 
earlier. 
;need to fix something, but idc atm so I just restore iriginal value to the dimension thingy;) 
dim_xy=128 
rkvmap=fltarr(dim_xy+30,1,dim_z+30) 
k1map=fltarr(dim_xy+30,1,dim_z) 
k2map=fltarr(dim_xy+30,1,dim_z-30) 
k3map=fltarr(dim_xy+30,1,dim_z-60) 
 
;The Array NeedVs is the one restored from the kartkoords.sav files, containing 4 variables describing 
the 
;location and approximate size of the tumour. newz is the number of slices in the z plane that is contains 
tumour tissue 
;to be accurate, it contains the start and stop of the z range, and what is hopefully the center value in the 
x and y direction. 
;This part of the program will unfourtunatly have to be rewritten if the size of the tumours is larger than 
the ones I've looked at. 
newz=NeedVs(2)-NeedVs(1) 
;Theese lines places slices of the tumour into the k-maps, the are placed next to eachother in ascending 
order. 
for j1=0, 8  do begin 
  rkvmap(1+(12*j1):9+(12*j1),0,(dim_z-newz-2)+20:(dim_z-2)+20)=rkv(NeedVs(3)-
4:NeedVs(3)+4,NeedVs(0)-4+j1,NeedVs(1):NeedVs(2)) 
  k1map(1+(12*j1):9+(12*j1),0,(dim_z-newz-2)-10:(dim_z-2)-10)=k1(NeedVs(3)-
4:NeedVs(3)+4,NeedVs(0)-4+j1,NeedVs(1):NeedVs(2)) 
  k2map(1+(12*j1):9+(12*j1),0,(dim_z-newz-2)-40:(dim_z-2)-40)=k2(NeedVs(3)-
4:NeedVs(3)+4,NeedVs(0)-4+j1,NeedVs(1):NeedVs(2)) 
  k3map(1+(12*j1):9+(12*j1),0,(dim_z-newz-2)-70:(dim_z-2)-70)=k3(NeedVs(3)-
4:NeedVs(3)+4,NeedVs(0)-4+j1,NeedVs(1):NeedVs(2)) 
endfor 
;All the stuff below is just spesifics to create the Kmap picture with text and all that 
loadct, 33 
XPalette, /BLOCK 
window, 3, xsize=4*(dim_xy+30), ysize=4*(dim_z+30) 
tvscl, rebin(rkvmap(*,0,*),4*(dim_xy+30), 1, 4*(dim_z+30), 1, /SAMPLE) 
tvscl, rebin(k1map(*,0,*),4*(dim_xy+30), 1, 4*dim_z, 1, /SAMPLE) 
tvscl, rebin(k2map(*,0,*),4*(dim_xy+30), 1, 4*(dim_z-30), 1, /SAMPLE) 
tvscl, rebin(k3map(*,0,*),4*(dim_xy+30), 1, 4*(dim_z-60), 1, /SAMPLE) 
loadct, 0 
xyouts, 15,475, 'rkv map',  CHARSIZE=2, COLOR=255, /DEVICE 
xyouts, 15,355, 'k1 map',  CHARSIZE=2, COLOR=255, /DEVICE 
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xyouts, 15,235, 'k2 map',  CHARSIZE=2, COLOR=255, /DEVICE 
xyouts, 15,115, 'k3 map',  CHARSIZE=2, COLOR=255, /DEVICE 
xyouts, 15,20, 'Yvalues from bottom up --------->',  CHARSIZE=2, COLOR=255, /DEVICE 
heirkv=rkv(where(rkv gt 0)) 
heik1=k1(where(k1 gt 0)) 
heik2=k2(where(k2 gt 0)) 
heik3=k3(where(k3 gt 0)) 
xyouts, 70,465, 'mean rkv:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 70,345, 'mean k1:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 70,225, 'mean k2:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 70,105, 'mean k3:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 110,465, mean(heirkv),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 110,345, mean(heik1),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 110,225, mean(heik2),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 110,105, mean(heik3),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 200,465, ',min rkv:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 200,345, ',min k1:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 200,225, ',min k2:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 200,105, ',min k3:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,465, min(heirkv),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,345, min(heik1),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,225, min(heik2),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,105, min(heik3),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 350,465, ',max rkv:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 350,345, ',max k1:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 350,225, ',max k2:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 350,105, ',max k3:',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 390,465, max(heirkv),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 390,345, max(heik1),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 390,225, max(heik2),  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 390,105, max(heik3),  CHARSIZE=1, COLOR=255, /DEVICE 
ParamsMap_jpg=TVREAD(Filename = 'ParamsMap', /JPEG, QUALITY = 100) 
;And these lines makes histograms of the k-values and save em as images 
n_bins=40 
k1_hist = HISTOGRAM(heik1, NBINS = n_bins) 
k1_stolpestr = DOUBLE((MAX(heik1) - MIN(heik1))/(n_bins)) 
k1_stolper = k1_stolpestr*FINDGEN(n_bins) 
WINDOW, 5, TITLE = 'k1 histogram' 
PLOT, k1_stolper, k1_hist, YRANGE = [0, MAX(k1_hist)+1], PSYM = 10, BACKGROUND = 255, 
COLOR = 0, XTITLE = 'k1 value', YTITLE = 'intensity' 
k1hist_jpg = TVREAD(filename = 'k1hist', /JPEG, QUALITY = 100) 
n_bins=40 
k2_hist = HISTOGRAM(heik2, NBINS = n_bins) 
k2_stolpestr = DOUBLE((MAX(heik2) - MIN(heik2))/(n_bins)) 
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k2_stolper = k2_stolpestr*FINDGEN(n_bins) 
WINDOW, 6, TITLE = 'k2 histogram' 
PLOT, k2_stolper, k2_hist, YRANGE = [0, MAX(k2_hist)+1], PSYM = 10, BACKGROUND = 255, 
COLOR = 0, XTITLE = 'k2 value', YTITLE = 'intensity' 
k2hist_jpg = TVREAD(filename = 'k2hist', /JPEG, QUALITY = 100) 
n_bins=40 
k3_hist = HISTOGRAM(heik3, NBINS = n_bins) 
k3_stolpestr = DOUBLE((MAX(heik3) - MIN(heik3))/(n_bins)) 
k3_stolper = k3_stolpestr*FINDGEN(n_bins) 
WINDOW, 7, TITLE = 'k3 histogram' 
PLOT, k3_stolper, k3_hist, YRANGE = [0, MAX(k3_hist)+1], PSYM = 10, BACKGROUND = 255, 
COLOR = 0, XTITLE = 'k3 value', YTITLE = 'intensity' 
k3hist_jpg = TVREAD(filename = 'k3hist', /JPEG, QUALITY = 100) 
n_bins=40 
rkv_hist = HISTOGRAM(heirkv, NBINS = n_bins) 
rkv_stolpestr = DOUBLE((MAX(heirkv) - MIN(heirkv))/(n_bins-1)) 
rkv_stolper = min(heirkv)+rkv_stolpestr*FINDGEN(n_bins) 
WINDOW, 8, TITLE = 'rkv histogram' 
PLOT, rkv_stolper, rkv_hist, YRANGE = [0, MAX(rkv_hist)+1], PSYM = 10, BACKGROUND = 255, 
COLOR = 0, XTITLE = 'rkv value', YTITLE = 'intensity' 
rkvhist_jpg = TVREAD(filename = 'rkvhist', /JPEG, QUALITY = 100) 
print, 
median(heik1),min(heik1),max(heik1),median(heik2),min(heik2),max(heik2),median(heik3),min(heik3),max(heik3),
median(heirkv) 
end 
Method for finding the plasmafunction 
function findheartfunction ,dim_xy, dim_z, time, bilder 
dim_time=n_elements(time) 
unsatisf1=1 
default=1 
print, 'Have you already got a heartfunction for this mouse?' 
alreadyHF=0 
read, alreadyHF, prompt="Do you got a heartfunction for this mouse? " 
if alreadyHF then begin 
 print, 'Choose folder for heartfunction extraction' 
 fileloc2='' 
 read, fileloc2, prompt="Enter extracion location" 
 cd, fileloc2 
 unsatisf1=0 
 restore, filename='centreOfHeart.sav' 
  bilde=fltarr(dim_xy, dim_xy, dim_z) 
 for i=0, 4 do begin 
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  bilde=bilde+bilder(*,*,*, i) 
 endfor 
endif 
loadct, 33 
while unsatisf1 do begin 
 print, 'Do you want to use default settings?' 
 read, default, prompt="Use default settings? " 
 if not default then begin 
  print, 'Choose start and stop for time averaging' 
  read, start, stopp, prompt="Enter start and stop for time averaging: " 
 endif 
 if default then begin 
  start=0 
  stopp=4 
 endif 
 bilde=fltarr(dim_xy, dim_xy, dim_z) 
 for i=start, stopp do begin 
  bilde=bilde+bilder(*,*,*, i) 
 endfor 
 scalar=1 
 
 if not default then begin 
  print, 'Choose imgage scaling (default is 1)' 
  read, scalar, prompt="Enter new image scaling: " 
 endif 
 window, 0, TITLE = 'Choose Y-value' 
 tvscl, rebin(bilde(*,*,40), 4*dim_xy, 4*dim_xy,  1, /SAMPLE) < scalar*max(bilde) 
 cursor, xpo, ypo, 4, /DEVICE 
 yvalue=round(ypo/4.0) 
   window, 0, xsize=512, ysize=512, TITLE = 'Choose Slice' 
 tvscl, rebin(bilde(*,yvalue,*), 4*dim_xy, 1, 4*dim_z, /SAMPLE) < scalar*max(bilde) 
 cursor, xpo, ypo, 4, /DEVICE 
 xpo=round(xpo/4.0) 
 ypo=round(ypo/4.0) 
 snitt=ypo 
 print, 'snitt valgt;' 
 print, snitt 
 window, 0, TITLE = 'Choose Seed Location' 
 tvscl, rebin(bilde(*,*,snitt), 4*dim_xy, 4*dim_xy, 1, /SAMPLE) < scalar*max(bilde) 
 ;tv, rebin(bild_btscl(*,72,*, 19),4*dim_xy, 1, 4*dim_z, 1, /SAMPLE) 
 cursor, xpo, ypo, 4, /DEVICE 
 xpo=round(xpo/4.0) 
 ypo=round(ypo/4.0) 
 reg=intarr(dim_xy, dim_xy) 
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 reg(xpo-1:xpo+1, ypo)=1 
 reg(xpo, ypo-1:ypo+1)=1 
 print, xpo 
 print, ypo 
 reg_3d=intarr(dim_xy, dim_xy, dim_z) 
 reg_3d(*,*,snitt)=reg(*,*) 
 cross_3d=where(reg_3d eq 1) 
 
 
 print, 'Are you unsatisfied with the seed location?' 
 read, mhm, prompt="Are you unsatisfied with the seed location? " 
 unsatisf1 = mhm 
endwhile 
heartregion=REGION_GROW(bilde,cross_3d, STDDEV_MULTIPLIER=7.0) 
displayGrown_3d=intarr(dim_xy, dim_xy, dim_z) 
displayGrown_3d(heartregion)=1 
if not default then begin 
 print, 'Do you want to see a video of the grown region? 
 read, videogrown, prompt="Do you want to see a video of the grown region? " 
 if videogrown then begin 
  window, 1, xsize=512, ysize=512, TITLE = 'grown' 
  for i=ypo-7, ypo+7 do begin 
   ;tvscl, rebin(bilde(*,i,*), 4*dim_xy, 1, 4*dim_z, /SAMPLE) < 0.2*max(bilde) 
   ;stop 
   tvscl, rebin(bilde(*,i,*)*((1-displayGrown_3d(*,i,*))), 4*dim_xy, 1, 4*dim_z, 
/SAMPLE) < 0.7*max(bilder) 
   ;stop 
   wait, 1 
  endfor 
 endif 
endif 
;Shall we try to limit the region then? 
centre=array_indices(bilde, cross_3d(2)) 
print, 'Choose where to save data' 
fileloc='' 
read, fileloc, prompt="Enter save location" 
cd, fileloc 
save, filename='centreOfHeart.sav', cross_3d 
wantlimit=1 
entiresphere=0 
radius=3 
if not default then begin 
 print, 'Do you want to limit the region to a sphere, with the choosen seed location as the centre?' 
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 read, wantlimit, prompt="Do you want to limit the region to a sphere, with the choosen seed 
location as the centre?: " 
 if wantlimit then begin 
  print, 'In that case, do you want to use the entire sphere as your new heartregion?' 
  read, entiresphere, prompt="Use entire sphere as new heartregion?" 
  print, 'Oh and btw, you must give the radius of the sphere. A radius of 5 voxels shoud 
contain the entire heart and then some' 
  read, radius, prompt="Enter raduis of sphere: " 
 endif 
endif 
if entiresphere then begin 
 heartregion=REGION_GROW(bilde,cross_3d, STDDEV_MULTIPLIER=100.0) 
endif 
time_cut=5 
i=long(0) 
ind_time_cut=lonarr(n_elements(heartregion)) 
forhold=fltarr(n_elements(heartregion)) 
j=long(0) 
while i lt n_elements(heartregion)-1 do begin 
 index=array_indices(bilde, heartregion(i)) 
 time_ind_pre=where(time le time_cut) 
 maks_pre_cut=float(max(bilder(index(0), index(1), index(2), 
min(time_ind_pre):max(time_ind_pre)))) 
 time_ind_post=where(time gt time_cut) 
 maks_post_cut=float(max(bilder(index(0), index(1), index(2), 
min(time_ind_post):max(time_ind_post)))) 
 
 if wantlimit then begin 
  distance=sqrt(((index(0)-centre(0))^2)+((index(1)-centre(1))^2)+((index(2)-
centre(2))^2)) 
  if distance lt (radius+0.0001) and maks_pre_cut gt maks_post_cut then begin 
   ind_time_cut(j)=heartregion(i) 
   tall_pre=max(bilder(index(0), index(1), index(2), 
min(time_ind_pre):max(time_ind_pre))) 
   tall_post=float(mean(bilder(index(0), index(1), index(2), dim_time-6:dim_time-
1))) 
   forhold(j)=tall_pre/tall_post 
  j=j+1 
  endif 
 endif 
 i=i+1 
endwhile 
 
sorte=reverse(sort(forhold)) 
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func_average=0 
k=long(0) 
k5=0 
n_functions=3 
if not default then begin 
 print, 'How many individual plasmafunctions do you want to display?' 
 read, n_functions, prompt="Enter number of displayed plasmafunctions: " 
endif 
while k lt j do begin 
 ind_max=sorte(k) 
 ind_max_3d=ind_time_cut(ind_max) 
 ind_max_3d_xyz=array_indices(bilde, ind_max_3d) 
 func_orig=reform(bilder(ind_max_3d_xyz(0), ind_max_3d_xyz(1), ind_max_3d_xyz(2), *)) 
 if k lt n_functions and not alreadyHF then begin 
  loadct, 0 
  oplot, time, func_orig 
 endif 
 if forhold(sorte(k)) gt 4 then begin 
  func_average=func_average+func_orig 
  k5=k5+1 
 endif 
 k=k+1 
endwhile 
func_average=func_average/k5 
;print, func_average 
;time(where(time lt 100))=time(where(time lt 100))*100/60. 
;time=time/100. 
ind_min=where(func_average eq max(func_average)) 
ind_min=ind_min(0) 
parinfo = replicate({value:0.0D, fixed:0, limited:[0,0], limits:[0.D,0], relstep:0.0D, tied:''}, 4) 
parinfo[0:3].limited[0] = 1 
parinfo[0:3].limits[0]  = 0.D 
parinfo[0:3].relstep[0]  = double(1e-4) 
parinfo[2].tied = strcompress(string(max(func_average)), /REMOVE_ALL)+'-P[0]' ; DETTE ER 
'TRIKSET'!!!! 
a_in=0.8*max(func_average) 
b_in=2.0 
c_in=0.2*max(func_average) 
d_in=0.1 
par=double([a_in, b_in, c_in, d_in]) 
func_err=time(ind_min:dim_time-1)*0+1.0 
min_time=time(ind_min) 
loadct, 0 
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res=MPFITFUN('arterie', time(ind_min:dim_time-1)-min_time(0), 
double(func_average(ind_min:dim_time-1)), func_err, par, PARINFO=parinfo, YFIT=func_fit, STATUS=status, 
QUIET=1, MAXITER=500, FTOL=1e-6, /DOUBLE) 
window, 2, xsize=512, ysize=512 
plot, time, func_average, PSYM=4 
loadct, 33 
oplot, time(ind_min:dim_time-1), func_fit, thick=2 
heartF_jpg=TVREAD(Filename = 'heartF', /JPEG, QUALITY = 100) 
func=func_average 
func(ind_min:dim_time-1)=func_fit 
return, func 
END 
Method for delinating the tumor 
function findtumorregion, bilder 
region=fix(bilder) 
region(*)=0 
si=size(bilder) 
dim_xy=si(1) 
dim_z=si(3) 
dim_time=n_elements(time) 
unsatisf1=1 
scalar=0.02 
choise=0 
while unsatisf1 do begin 
 reg=0 
 region(*)=0 
 window, 0, TITLE = 'Choose Y-value' 
 tvscl, rebin(bilder(*,*,60), 4*dim_xy, 4*dim_xy, 1, /SAMPLE) < scalar*max(bilder) 
 cursor, xpo, ypo, 4, /DEVICE 
 yvalue=round(ypo/4.0) 
 if choise eq 2 then begin 
 print, 'Do you want to eter yvalue found in video instead?' 
 print, 'Current yvalue is: ', yvalue 
 read, yvalue, prompt="Enter new yvalue: " 
 endif 
 bild_btscl=bytscl(bilder, MAX=scalar*max(bilder)) 
 tv, rebin(bild_btscl(*,yvalue,*),4*dim_xy, 1, 4*dim_z, /SAMPLE) 
   window, 0, xsize=dim_xy*4, ysize=dim_z*4, TITLE = 'Choose first slice of tumor region' 
    tv, rebin(bild_btscl(*,yvalue,*),4*dim_xy, 1, 4*dim_z, /SAMPLE) 
 cursor, xpo, ypo, 4, /DEVICE 
 xpo=round(xpo/4.0) 
 ypo=round(ypo/4.0) 
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 xvalue=xpo 
 firstslice=ypo 
 print, 'firstslice:' 
 print, firstslice 
 
   window, 0,  TITLE = 'Choose last slice of tumor region' 
 tv, rebin(bild_btscl(*,yvalue,*),4*dim_xy, 1, 4*dim_z,  /SAMPLE) 
 cursor, xpo, ypo, 4, /DEVICE 
 xpo=round(xpo/4.0) 
 ypo=round(ypo/4.0) 
 lastslice=ypo 
 print, 'lastslice:' 
 print, lastslice 
 tsk=intarr(2, 3, 2) 
 for i=firstslice, lastslice do begin 
  window, 0, xsize=dim_xy*4, ysize=dim_z*4, TITLE = 'Draw ROI around tumor' 
  tvscl, rebin(bilder(*,*,i), 4*dim_xy, 4*dim_xy, 1,/SAMPLE) < scalar*max(bilder) 
  ;tegn inn interesseområde - roi er en liste endimesjonale adresser i et 512x512 bilde 
  roi=DEFROI(4*dim_xy,4*dim_xy, /RESTORE) 
  reg=intarr(4*dim_xy,4*dim_xy) 
  reg(roi)=1 
  reg=rebin(reg, dim_xy, dim_xy, /sample) 
  region(*,*,i)=reg 
  
  endfor 
 print, 'Are you unsatisfied with your tumor region?' 
 read, mhm, prompt="Are you unsatisfied with your tumor region? " 
 unsatisf1 = mhm 
 if unsatisf1 then begin 
  print, 'Choose new image scaling (default was 0.02)' 
  read, scalar, prompt="Enter new image scaling: " 
  print, 'Do you want to see video 1 or 2 too look for tumor?' 
  read, choise, prompt ="Enter videonumber: " 
  ok=videos(dim_xy,dim_z,dim_time,bilder,choise, time,scalar) 
 endif 
endwhile 
NeedVs=intarr(4) 
NeedVs(0)=yvalue 
NeedVs(1)=firstslice 
NeedVs(2)=lastslice 
NeedVs(3)=xvalue 
save, filename='kartkoord.sav', NeedVs 
return, region 
END 
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Method for obtaining arrays containing all normalized TACs wanted 
DEVICE, DECOMPOSED = 0 
common art, arter 
!EXCEPT=0 
;loadct, 33 
;XPalette, /BLOCK 
print, 'Choose dataset' 
datset='' 
read, datset, prompt="Enter datasetnr" 
Dataset=finddataset(datset) 
findnumber=size(Dataset) 
n_tumours=findnumber(1)/2. 
timevector=1.0 
Superarray1=1.0 
Superarray2=1.0 
Superarray3=1.0 
Superarray4=1.0 
for iii=0, n_tumours-1 do begin 
fileloc=Dataset(iii) 
cd, fileloc 
files = FILE_SEARCH('*', COUNT=n_images) 
sort_ind=sort(inst) 
bilder=dblarr(dim_xy, dim_xy, dim_z, dim_time) 
time=fltarr(dim_time) 
if iii eq 0 then begin 
 Superarray1=fltarr(10,n_tumours) 
 Superarray2=fltarr(10,n_tumours) 
 if dim_time gt 20 then begin 
  Superarray3=fltarr(10,n_tumours) 
  Superarray4=fltarr(10,n_tumours) 
 endif 
endif 
;some recurring code has been deleted 
results=findnormalizationconstant(dim_xy,dim_z,time,bilder,Dataset,iii) 
normconstant=results(0) 
restore, filename='tumorRegion.sav' 
print, normconstant 
index=where(TumourR) 
stat=intarr(dim_xy,dim_xy,dim_z) 
tumourfunction=fltarr(dim_time) 
i=0 
while i lt n_elements(index) do begin 
 ind=array_indices(stat, index(i)) 
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 tumourdummy=reform(bilder(ind(0),ind(1),ind(2),*)) 
 tumourfunction=tumourfunction+tumourdummy 
 i=i+1 
endwhile 
tumourfunction=tumourfunction/(normconstant*n_elements(index)) 
print, Dataset(iii+findnumber) 
print, normconstant 
timeshift=realtime(results(1)) 
realtime=realtime-timeshift 
newtimearray=realtime(results(1):dim_time-1) 
newtumourfunction=tumourfunction(results(1):dim_time-1) 
tumourfunction=interpol(newtumourfunction,newtimearray,timevector) 
for lol=0, n_elements(timevector)-1 do begin 
 if lol lt 10 then Superarray1(lol,iii)=tumourfunction(lol) 
 if lol lt 20 and lol gt 9 then Superarray2(lol-10,iii)=tumourfunction(lol) 
 if lol lt 30 and lol gt 19 then Superarray3(lol-20,iii)=tumourfunction(lol) 
 if lol lt 40 and lol gt 29 then Superarray4(lol-30,iii)=tumourfunction(lol) 
endfor 
endfor 
print, Superarray1 
print, 'halllooooeen' 
print, Superarray2 
print, 'woot' 
print, Superarray3 
print, 'Oh yeah' 
print, Superarray4 
cd, 'F:\Gistmus\Data\GruppePercentiler' 
save, filename='sa1.sav', Superarray1 
save, filename='sa2.sav', superarray2 
save, filename='sa3.sav', superarray3 
save, filename='sa4.sav', superarray4 
; The following part will sadly still have to be ad hoc ie  you have to change source code. 
percentilesagain=fltarr(n_elements(timevector)) 
for i3=0, n_elements(timevector)-1 do begin 
 if i3 lt 10 then begin 
  g0=Superarray1(i3,0:11) 
  g1=Superarray1(i3,12:21) 
 endif 
 if i3 gt 9 and i3 lt 20 then begin 
  g0=Superarray2(i3-10,0:11) 
  g1=Superarray2(i3-10,12:21) 
 endif 
 if i3 gt 19 and i3 lt 30 then begin 
  g0=Superarray3(i3-20,0:11) 
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  g1=Superarray3(i3-20,12:21) 
 endif 
 if i3 gt 29 and i3 lt 40 then begin 
  g0=Superarray4(i3-30,0:11) 
  g1=Superarray4(i3-30,12:21) 
 endif 
 result=tm_test(g0,g1) 
 percentilesagain(i3)=result(1) 
endfor 
window, 1 
plot, percentilesagain , PSYM=4, BACKGROUND=255, COLOR=0 
treshold=fltarr(n_elements(timevector)) 
treshold(0:n_elements(timevector)-1)=0.05 
oplot, treshold, COLOR=0 
stop 
end 
 
method for doing the patlak plots 
;some recurring code has been deleted here  
Kfromk=(res(0)*res(2))/(res(1)+res(2)) 
print, 'K* estimated from k-parameters' 
print, Kfromk 
KK(iii)=Kfromk 
loadct, 0 
dim_time=dim_time 
func_tissue=func_free_avg+func_bound_avg 
Patlakx=fltarr(dim_time) 
Patlaky=fltarr(dim_time) 
for ij=1, dim_time-1 do begin 
 
 if arterieF(ij) gt 0 then begin 
  ind=where(time lt (time(ij)+0.01)) 
  Patlakx(ij)=(int_tabulated(time(ind), arterieF(ind)))/arterieF(ij) 
  Patlaky(ij)=func_tissue(ij)/arterieF(ij) 
 endif 
endfor 
window, 0, xsize=700, ysize=700 
;plot, Patlakx, Patlaky 
plot, Patlakx, Patlaky, psym=4 
Patlakxend=Patlakx((dim_time-4):(dim_time-1)) 
Patlakyend=Patlaky((dim_time-4):(dim_time-1)) 
KfromP=linfit(Patlakxend,Patlakyend) 
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print, 'K* estimated from Patlak plot' 
print, KfromP(1) 
PatlakK(iii)=KfromP(1) 
lala=KfromP(1)*Patlakxend 
lala=lala+KfromP(0) 
oplot, Patlakxend, lala 
stop 
endfor 
end 
Method for creating the percentile charts 
DEVICE, DECOMPOSED = 0 
;This program is to do the ultimate test, check the percentile  
print, 'Choose dataset (5)' 
datset='' 
read, datset, prompt="Enter datasetnr" 
Dataset=finddataset(datset) 
findnumber=(size(Dataset)) 
n_tumors=findnumber(1)/2 
Percentilearrayk1=fltarr(102) 
Percentilearrayk1(0)=0 
Percentilearrayk1(101)=0 
Percentilearrayk2=fltarr(102) 
Percentilearrayk2(0)=0 
Percentilearrayk2(101)=0 
Percentilearrayk3=fltarr(102) 
Percentilearrayk3(0)=0 
Percentilearrayk3(101)=0 
for i1=1, 100 do begin 
ArrayG0k1=fltarr(12) 
ArrayG1k1=fltarr(8) 
ArrayG0k2=fltarr(12) 
ArrayG1k2=fltarr(8) 
ArrayG0k3=fltarr(12) 
ArrayG1k3=fltarr(8) 
g0counter=0 
g1counter=0 
for i=0, n_tumors-1 do begin 
 cd, Dataset(i+n_tumors) 
 restore, filename='k1.sav' 
 restore, filename='k2.sav' 
 restore, filename='k3.sav' 
 k1array=k1(where (k1 gt 0)) 
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 k2array=k2(where (k2 gt 0)) 
 k3array=k3(where (k3 gt 0)) 
 if Dataset(i) eq 0 then begin 
  perck1=prank(k1array,i1) 
  perck2=prank(k2array,i1) 
  perck3=prank(k3array,i1) 
  ArrayG0k1(g0counter)=perck1 
  ArrayG0k2(g0counter)=perck2 
  ArrayG0k3(g0counter)=perck3 
  g0counter=g0counter+1 
 endif 
 if Dataset(i) eq 1 then begin 
  perck1=prank(k1array,i1) 
  perck2=prank(k2array,i1) 
  perck3=prank(k3array,i1) 
  ArrayG1k1(g1counter)=perck1 
  ArrayG1k2(g1counter)=perck2 
  ArrayG1k3(g1counter)=perck3 
  g1counter=g1counter+1 
 endif 
endfor 
resultk1=TM_TEST(ArrayG0k1,ArrayG1k1) 
resultk2=TM_TEST(ArrayG0k2,ArrayG1k2) 
resultk3=TM_TEST(ArrayG0k3,ArrayG1k3) 
if i1 eq 50 then stop 
Percentilearrayk1(i1)=resultk1(1) 
Percentilearrayk2(i1)=resultk2(1) 
Percentilearrayk3(i1)=resultk3(1) 
endfor 
hello=fltarr(102) 
hello[0:101]=0.05 
;t test (mean-test)/(std/(sqrt(n))) 
;TM_TEST gir [t,p] 
n_bins=102 
Stolpestr = 1 
Stolper = FINDGEN(n_bins) 
loadct, 0 
cd, 'F:\DATA PET forsøk\Grupperpercentiler' 
WINDOW, 1, TITLE = 'Percentiles k1' 
PLOT, Stolper, Percentilearrayk1, YRANGE = [0, 1.1*Max(Percentilearrayk1)], PSYM = 10, 
BACKGROUND = 255, COLOR = 0, XTITLE = 'Percentiles k1', YTITLE = 'p-value' 
;FinalAllk1g0hist_jpg = TVREAD(filename = 'FinalAllk1g0hist', /JPEG, QUALITY = 100) 
loadct, 33 
oplot, hello, color = 220 
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loadct, 0 
Percentilearrayk1_jpg = TVREAD(filename = 'Percentilearrayk1', /JPEG, QUALITY = 100) 
WINDOW, 2, TITLE = 'Percentiles k2' 
PLOT, Stolper, Percentilearrayk2, YRANGE = [0, 1.1*Max(Percentilearrayk2)], PSYM = 10, 
BACKGROUND = 255, COLOR = 0, XTITLE = 'Percentiles k2', YTITLE = 'p-value' 
loadct, 33 
oplot, hello, color=220 
loadct, 0 
Percentilearrayk2_jpg = TVREAD(filename = 'Percentilearrayk2', /JPEG, QUALITY = 100) 
WINDOW, 3, TITLE = 'Percentiles k3' 
PLOT, Stolper, Percentilearrayk3, YRANGE = [0, 1.1*Max(Percentilearrayk3)], PSYM = 10, 
BACKGROUND = 255, COLOR = 0, XTITLE = 'Percentiles k3', YTITLE = 'p-value' 
loadct, 33 
oplot, hello, color=220 
loadct, 0 
Percentilearrayk3_jpg = TVREAD(filename = 'Percentilearrayk3', /JPEG, QUALITY = 100) 
End 
Method for checking radiell dependency 
 
DEVICE, DECOMPOSED = 0 
print, 'Choose dataset' 
datset='' 
read, datset, prompt="Enter datasetnr" 
Dataset=finddataset(datset) 
findnumber=size(Dataset) 
n_tumours=findnumber(1)/2. 
CorrArr=fltarr(n_tumours) 
MaxDistArr=fltarr(n_tumours) 
;MegaDistanceg0=fltarr(10000) 
Megak1g0=fltarr(8) 
Megak2g0=fltarr(8) 
Megak3g0=fltarr(8) 
MegaMeRag0=fltarr(8) 
MegaCountg0=0 
Megak1g1=fltarr(8) 
Megak2g1=fltarr(8) 
Megak3g1=fltarr(8) 
MegaMeRag1=fltarr(8) 
MegaCountg1=0 
for iii=0, n_tumours-1 do begin 
cd, Dataset(iii+n_tumours) 
restore, filename='k1.sav' 
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restore, filename='k2.sav' 
restore, filename='k3.sav' 
restore, filename='tumorRegion.sav' 
dim_xy=128 
dim_z=9 
MeRa=fltarr(dim_xy,dim_xy,dim_z) 
for xlol = 0, dim_xy-1 do begin 
 for ylol = 0, dim_xy-1 do begin 
  for zlol =0, dim_z-1 do begin 
  k1val=k1(xlol,ylol,zlol) 
  k2val=k2(xlol,ylol,zlol) 
  k3val=k3(xlol,ylol,zlol) 
  if k1val gt 0 and k2val gt 0 and k3val gt 0 then begin 
   MeRa(xlol,ylol,zlol)=(k1val*k3val)/(k2val+k3val) 
  endif 
  endfor 
 endfor 
endfor 
;MeRa=((k1(where(k2))*k3(where(k2)))/(k2(where(k2))+k3(where(k2)))) 
save, filename='MeRa.sav', MeR 
jaha=where(TumourR gt 0) 
xretning=intarr(n_elements(jaha)) 
yretning=intarr(n_elements(jaha)) 
zretning=intarr(n_elements(jaha)) 
;restore den tingen tingen 
;dim_xy=bildecutting(2) 
dim_z=95 
noe=intarr(dim_xy,dim_xy,dim_z) 
for ix=0, n_elements(jaha)-1 do begin 
 ind=array_indices(noe, jaha(ix)) 
 xretning(ix)=ind(0) 
 yretning(ix)=ind(1) 
 zretning(ix)=ind(2) 
endfor 
xret=xretning(where(xretning gt 0)) 
yret=yretning(where(yretning gt 0)) 
zret=zretning(where(zretning gt 0)) 
index=fltarr(3) 
index(0)=median(xret) 
index(1)=median(yret) 
index(2)=median(zret) 
DistArr=fltarr(n_elements(jaha)) 
k1Arr=fltarr(n_elements(jaha)) 
k2Arr=fltarr(n_elements(jaha)) 
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k3Arr=fltarr(n_elements(jaha)) 
MeRaArr=fltarr(n_elements(jaha)) 
for xi=0, n_elements(jaha)-1 do begi 
 ;Allright, then to make an insane thingy to calculate a cricular thing 
 distance=sqrt((((index(0)-xret(xi))*0.87)^2)+(((index(1)-yret(xi))*0.87)^2)+(((index(2)-
zret(xi))*0.8)^2)) 
 DistArr(xi)=distance 
 k1Arr(xi)=k1(xret(xi),yret(xi),zret(xi)) 
 k2Arr(xi)=k2(xret(xi),yret(xi),zret(xi)) 
 k3Arr(xi)=k3(xret(xi),yret(xi),zret(xi)) 
 MeRaArr(xi)=MeRa(xret(xi),yret(xi),zret(xi)) 
endfor 
window, 0 
plot, DistArr, k1Arr, psym=4 
xyouts, 10,256, 'k1',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 180,8, 'Distance->',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,8, 'Correlation',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 300,8, correlate(DistArr, k1Arr),  CHARSIZE=1, COLOR=255, /DEVICE 
k1radiell = TVREAD(filename = 'k1radiell', /JPEG, QUALITY = 100) 
window, 1 
plot, DistArr, k2Arr, psym=4 
xyouts, 10,256, 'k2',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 180,8, 'Distance->',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,8, 'Correlation',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 300,8, correlate(DistArr, k2Arr),  CHARSIZE=1, COLOR=255, /DEVICE 
k2radiell = TVREAD(filename = 'k2radiell', /JPEG, QUALITY = 100) 
window, 2 
plot, DistArr, k3Arr, psym=4 
xyouts, 10,256, 'k3',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 180,8, 'Distance->',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,8, 'Correlation',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 300,8, correlate(DistArr, k3Arr),  CHARSIZE=1, COLOR=255, /DEVICE 
k3radiell = TVREAD(filename = 'k3radiell', /JPEG, QUALITY = 100) 
window, 3 
plot, DistArr, MeRaArr, psym=4 
xyouts, 10,256, 'Metabloic Rate',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 180,8, 'Distance->',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 250,8, 'Correlation',  CHARSIZE=1, COLOR=255, /DEVICE 
xyouts, 300,8, correlate(DistArr, MeRaArr),  CHARSIZE=1, COLOR=255, /DEVICE 
MeRaradiell = TVREAD(filename = 'MetabolicRateRradiell', /JPEG, QUALITY = 100 
print, correlate(DistArr, k3Arr) 
print, Dataset(iii+n_tumours) 
print,max(DistArr) 
CorrArr(iii)=correlate(DistArr, k3Arr) 
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MaxDistArr(iii)=max(DistArr) 
lulz=0 
if Dataset(iii) eq 0 then begin 
  
 
   
  Megak1g0(Megacountg0)=correlate(DistArr, k1Arr) 
  Megak2g0(Megacountg0)=correlate(DistArr, k2Arr) 
  Megak3g0(Megacountg0)=correlate(DistArr, k3Arr) 
  MegaMeRag0(Megacountg0)=correlate(DistArr, MeRaArr) 
  Megacountg0=Megacountg0+1 
 ;endfor 
endif 
if Dataset(iii) eq 1 then begin 
 
  ;MegaDistanceg1(Megacountg1)=DistArr(lulz) 
  Megak1g1(Megacountg1)=correlate(DistArr, k1Arr) 
  Megak2g1(Megacountg1)=correlate(DistArr, k2Arr) 
  Megak3g1(Megacountg1)=correlate(DistArr, k3Arr) 
  MegaMeRag1(Megacountg1)=correlate(DistArr, MeRaArr) 
  Megacountg1=Megacountg1+1 
 
endif 
 
endfor 
print, 'mean k1g0' 
print, median(Megak1g0) 
print, 'mean k2g0' 
print, median(Megak2g0) 
print, 'mean k3g0' 
print, median(Megak3g0) 
print, 'mean MeRag0' 
print, median(MegaMeRag0) 
print, 'mean k1g1' 
print, median(Megak1g1) 
print, 'mean k2g1' 
print, median(Megak2g1) 
print, 'mean k3g1' 
print, median(Megak3g1) 
print, 'mean MeRag1' 
print, median(MegaMeRag1) 
print, 'then the p-values' 
result=tm_test(Megak1g0,Megak1g1) 
print, result(1) 
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result=tm_test(Megak2g0,Megak2g1) 
print, result(1) 
result=tm_test(Megak3g0,Megak3g1) 
print, result(1) 
result=tm_test(MegaMeRag0,MegaMeRag1) 
print, result(1) 
end 
support porgrams, arterie 
Function arterie, x, par, F 
a=par(0) 
b=par(1) 
c=par(2) 
d=par(3) 
F=a*exp(-b*x)+c*exp(-d*x) 
return, F 
end 
bound 
Function bound, x, par, F 
common art 
k1=par(0) 
k2=par(1) 
k3=par(2) 
alfa1=0.5*(k2+k3+k4-sqrt(((k2+k3+k4)^2)-4*k2*k4)) 
alfa2=0.5*(k2+k3+k4+sqrt(((k2+k3+k4)^2)-4*k2*k4)) 
nel=n_elements(x) 
F=fltarr(nel) 
fak=k1*k3/(alfa2-alfa1) 
F1_h=exp(-alfa1*x(1:*))*total((x(1:*)-x(0:nel-2))*arter(1:*)*exp(alfa1*x(1:*)), /CUMULATIVE, /DOUBLE) 
F2_h=exp(-alfa2*x(1:*))*total((x(1:*)-x(0:nel-2))*arter(1:*)*exp(alfa2*x(1:*)), /CUMULATIVE, /DOUBLE) 
F1_v=exp(-alfa1*x(0:nel-2))*total((x(1:*)-x(0:nel-2))*arter(0:nel-2)*exp(alfa1*x(0:nel-2)), /CUMULATIVE, 
/DOUBLE) 
F2_v=exp(-alfa2*x(0:nel-2))*total((x(1:*)-x(0:nel-2))*arter(0:nel-2)*exp(alfa2*x(0:nel-2)), /CUMULATIVE, 
/DOUBLE) 
F(1:*)=fak*0.5*(F1_h+F1_v-F2_h-F2_v) 
return, F 
end 
 
free 
Function free, x, par, F 
common art 
k1=par(0) 
k2=par(1) 
k3=par(2) 
k4=par(3) 
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alfa1=0.5*(k2+k3+k4-sqrt(((k2+k3+k4)^2)-4*k2*k4)) 
alfa2=0.5*(k2+k3+k4+sqrt(((k2+k3+k4)^2)-4*k2*k4)) 
nel=n_elements(x) 
F=fltarr(nel) 
F1_h=(k1/(alfa2-alfa1))*(k4-alfa1)*exp(-alfa1*x(1:*))*total((x(1:*)-x(0:nel-2))*arter(1:*)*exp(alfa1*x(1:*)), 
/CUMULATIVE, /DOUBLE) 
F2_h=(k1/(alfa2-alfa1))*(alfa2-k4)*exp(-alfa2*x(1:*))*total((x(1:*)-x(0:nel-2))*arter(1:*)*exp(alfa2*x(1:*)), 
/CUMULATIVE, /DOUBLE) 
F1_v=(k1/(alfa2-alfa1))*(k4-alfa1)*exp(-alfa1*x(0:nel-2))*total((x(1:*)-x(0:nel-2))*arter(0:nel-
2)*exp(alfa1*x(0:nel-2)), /CUMULATIVE, /DOUBLE) 
F2_v=(k1/(alfa2-alfa1))*(alfa2-k4)*exp(-alfa2*x(0:nel-2))*total((x(1:*)-x(0:nel-2))*arter(0:nel-
2)*exp(alfa2*x(0:nel-2)), /CUMULATIVE, /DOUBLE 
F(1:*)=0.5*(F1_h+F1_v+F2_h+F2_v) 
return, F 
end 
trekomp 
Function trekomp, x, par, F 
common ar 
F=free(x, par)+bound(x,par) 
F=F+(par(4)*arter)  ;Change this when switching artery parameter on/off 
return, F 
end 
 
